[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tang-Du Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":621},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,56,0,25,[9,49,75,103,128,157,180,206,230,251,277,305,331,352,380,404,426,450,472,493,514,536,560,581,601],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100054309","phase-4-crisugabalin-in-nmosd-neuropathic-pain-a-randomized-double-blind-placebo-controlled-exploratory-trial-100054309",false,"NCT07699770","Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial","Efficacy and Safety of Crisugabalin in Treating Neuropathic Pain Related to Neuromyelitis Optica Spectrum Disorders: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled, Exploratory Trial","TERMINATOR","\\*\\*Inclusion Criteria:\\*\\*\n\nSubjects who meet all of the following criteria will be enrolled in this study:\n\n1. Able to understand and voluntarily sign the written informed consent form;\n2. Male or female aged between 18 years (inclusive) and 75 years;\n3. Diagnosed with aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) according to the International Panel for NMO Diagnosis (IPND, 2015) criteria;\n4. Patients with comorbid neuropathic pain, DN4 ≥ 4; no change in medication dosage within the past month;\n5. Numeric Rating Scale (NRS) for pain score ≥ 4 at screening;\n6. First-time use of Crisugabalin Capsules.\n\n\\*\\*Exclusion Criteria:\\*\\*\n\nSubjects who meet any of the following criteria will not be enrolled in this study:\n\n1. Presence of peripheral neuropathy or pain unrelated to NMOSD that, in the investigator's judgment, may confound the assessment;\n2. Known history of allergy to the investigational drug components, or to other drugs with similar chemical structures, or to any excipients;\n3. Prior use of pregabalin ≥ 300 mg\u002Fday, gabapentin ≥ 1200 mg\u002Fday, or mirogabalin ≥ 30 mg\u002Fday with lack of clinical efficacy as judged by the investigator;\n4. Severe liver or kidney function abnormalities, meeting any of the following clinical laboratory findings:\n\n1\\) Liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 × upper limit of normal (ULN); 2) Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m² (calculated using the simplified MDRD formula); 5. Women who are pregnant, planning to become pregnant during the study period, or currently breastfeeding; subjects who are unwilling to use reliable contraceptive measures (including condoms, spermicides, intrauterine devices, etc.) from the time of signing the ICF until 28 days after the last dose of the investigational drug; 6. Current use of IL-6 receptor blockers (e.g., tocilizumab, satralizumab); 7. History of suicidal behavior or suicidal ideation; 8. Participation in any other clinical study within 30 days prior to screening; 9. The investigator determines that there are other situations in which participation in the study is inappropriate.","ALL","18 Years","75 Years",{"count":22,"type":23},110,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.",[29,30],"Neuromyelitis Optica Spectrum Disorders (NMOSD)","Neuropathic Pain",[32,33,34,35],"neuromyelitis optica spectrum disorders","Neuropathic pain","Crisugabalin","NMOSD","NOT_YET_RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":23},"2026-06-15",{"date":44,"type":23},"2027-12-31",{"name":46,"class":47},"Tang-Du Hospital","OTHER",10,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100053495","the-effects-of-coenzyme-q10-pretreatment-on-ovarian-function-and-assisted-reproductive-outcomes-in-patients-with-ovarian-hyporesponsiveness-100053495","NCT07260773","The Effects of Coenzyme Q10 Pretreatment on Ovarian Function and Assisted Reproductive Outcomes in Patients With Ovarian Hyporesponsiveness.","The Effects of Coenzyme Q10 Pretreatment on Ovarian Function and Assisted Reproductive Outcomes in Patients With Poor Ovarian Response: A Single-Center Randomized Controlled Trial","Inclusion Criteria:\n\n* Individuals seeking IVF-ET fertility treatment;\n* Meeting the Bologna criteria for the definition of poor ovarian response (POR), specifically:\n* (1) Meeting 2 of the following 3 criteria:\n* ① Presence of high-risk factors for POR;\n* ② Previous cycle with ≤3 retrieved oocytes under a standard stimulation protocol;\n* ③ Abnormal ovarian reserve assessment: Antral follicle count (AFC) \\\u003C5 or Anti-Müllerian hormone (AMH) \\\u003C1.1 ng\u002FmL.\n\nor\n\n* (2) Patients with normal age or ovarian reserve function who experience poor ovarian response (POR) after two consecutive cycles of maximum ovarian stimulation protocols;\n* BMI between 18.5-28.0 kg\u002Fm²\n* Voluntarily participate and sign an informed consent form.\n\nExclusion Criteria:\n\n* Age ≥40 years;\n* Baseline FSH \\>25 U\u002FL;\n* Endocrine disorders (e.g., diabetes, thyroid disease) or autoimmune diseases (e.g., rheumatoid arthritis, lupus, Crohn's disease), chromosomal abnormalities, uterine malformations;\n* History of ovarian surgery; history of uterine surgery; adenomyosis;\n* History of more than 3 cycles of controlled ovarian stimulation (COS);\n* Male infertility;\n* Use within the past 3 months of medications that may affect ovarian reserve or ovarian responsiveness (e.g., oral contraceptives, glucocorticoids, antioxidant supplements, insulin sensitizers, DHEA, growth hormone, etc.);\n* Use of traditional Chinese medicine within the past 3 months;\n* Known allergy to Coenzyme Q10 or panthenol (water-soluble isomer of CoQ10);\n* PGT (Preimplantation Genetic Testing) population;\n* Acute or chronic renal insufficiency, hemodialysis treatment, history of severe renal impairment;\n* Infectious diseases such as HIV, active hepatitis, history of metabolic acidosis, tuberculosis;\n* Cardiovascular events within 3 months: coronary artery disease\u002Fmyocardial infarction\u002Fclinically significant congestive heart failure; stroke\u002Ftransient ischemic attack; deep vein thrombosis\u002Fpulmonary embolism; uncontrolled hypertension (systolic ≥160 mmHg or diastolic ≥90 mmHg); diagnosed diabetes; coronary intervention or coronary artery bypass graft surgery;\n* Neurological disorders such as dementia (e.g., Alzheimer's\u002FParkinson's) or use of related medications;\n* History of psychological\u002Fpsychiatric disorders and use of antiepileptic, antidepressant, or similar medications;\n* History of cancer, radiation therapy, or chemotherapy;\n* Unwillingness to take supplements provided by this study;\n* Alcoholics, smokers, or individuals with substance dependence;\n* Participants in other clinical trials within the past month;\n* Patients deemed ineligible for enrollment by the investigator.","FEMALE","20 Years","39 Years",{"count":60,"type":23},128,[62],"NA","This prospective, randomized, double-blind, controlled study will be conducted at Tangdu Hospital, Air Force Medical University. It plans to enroll 128 patients with poor ovarian response for a 2-year study. The primary objective is to investigate the effects of exogenous coenzyme Q10 supplementation as pre-treatment on ovarian function and assisted reproductive clinical outcomes in patients with poor ovarian response.\n\nStudy Hypothesis: Coenzyme Q10 therapy is expected to effectively enhance ovarian function and improve assisted reproductive outcomes in patients with poor ovarian response, while demonstrating favorable safety profiles.",[65],"Ovarian Response",[67],"Ovarian function","2026-07-08",{"date":39,"type":40},{"date":71,"type":23},"2026-07",{"date":73,"type":23},"2027-03",{"name":46,"class":47},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100645114","phase-2-neoadjuvant-short-course-radiotherapy-plus-tislelizumab-and-chemotherapy-for-locally-advanced-resectable-esophageal-squamous-cell-carcinoma-100645114","NCT07678580","Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","Neoadjuvant Short-Course Radiotherapy Followed by Tislelizumab Combined With Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter, Exploratory Study","Inclusion Criteria:\n\n* Voluntarily provided written informed consent prior to any study-related procedures\n* Aged 18 to 75 years, male or female\n* Life expectancy of at least 3 months\n* Predicted to achieve R0 surgical resection\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Histologically confirmed, treatment-naive, resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC) meeting the staging criteria: T1 N1-3 M0 or T2-4a N0-3 M0 (T2 ≥3 cm or poorly differentiated). No suspected metastatic cervical lymph nodes (except for upper thoracic esophageal cancer regional lymph nodes) on neck ultrasound or contrast-enhanced CT, and no distant metastasis on imaging\n* Presence of measurable tumor lesions.\n* Adequate organ function defined by laboratory parameters: Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL; platelet count ≥100×10⁹\u002FL; hemoglobin ≥90 g\u002FL. Total bilirubin ≤1.5×ULN; AST and ALT ≤2.5×ULN. Serum creatinine ≤1.5×ULN or calculated creatinine clearance ≥60 mL\u002Fmin. INR ≤1.5, PT and APTT ≤1.5×ULN\n* Men and women of childbearing potential must use effective contraception during treatment and for 6 months after the last dose of study treatment\n* Good compliance and ability to complete scheduled follow-up.\n\nExclusion Criteria:\n\n* Prior treatment with PD-1\u002FPD-L1 inhibitors or other immunomodulatory agents targeting T-cell receptors (e.g., CTLA-4, OX40)\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage\n* Active or suspected autoimmune disease, including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, except type 1 diabetes controlled by replacement therapy, hypothyroidism, or skin disorders not requiring systemic therapy\n* History of grade ≥2 interstitial lung disease\n* Systemic corticosteroids (\\>10 mg prednisone daily or equivalent) or other immunosuppressive agents within 14 days before first study treatment\n* Primary or acquired immunodeficiency, organ transplantation, allogeneic hematopoietic stem cell transplantation\n* Live vaccine within 4 weeks before first study treatment\n* Severe uncontrolled cardiovascular or cerebrovascular disease: Uncontrolled hypertension or pulmonary hypertension. Unstable angina, myocardial infarction, coronary artery bypass grafting, or stent implantation within 6 months. NYHA class ≥2 chronic heart failure. Left ventricular ejection fraction (LVEF) \\\u003C50%.\n\nClinically significant arrhythmia requiring treatment. Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months. Uncontrolled active infection requiring systemic antibiotics. Positive HIV test, active hepatitis B or hepatitis C infection (exceptions: HBV DNA \\\u003C500 IU\u002FmL; HCV RNA undetectable).\n\nActive pulmonary tuberculosis (TB). Other active malignancy within the previous 2 years, except adequately treated thyroid cancer, carcinoma in situ of the cervix, basal\u002Fsquamous cell skin cancer, or ductal carcinoma in situ of the breast\n\n* History of drug abuse or psychiatric disorder\n* Pregnant or lactating women\n* Any other severe medical, psychiatric, or laboratory abnormality that, in the investigator's opinion, would increase study-related risk or interfere with result interpretation.",{"count":83,"type":23},50,[85],"PHASE2","Neoadjuvant Short-Course Radiotherapy Followed by Tislelizumab Plus Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma This is a prospective, randomized, two-arm, parallel-group, multicenter, exploratory Phase II clinical trial. It aims to evaluate the efficacy and safety of neoadjuvant short-course radiotherapy followed by tislelizumab combined with chemotherapy in participants with locally advanced resectable esophageal squamous cell carcinoma (ESCC).\n\nEligible participants will be randomized in a 1:1 ratio to receive either low-dose or high-dose short-course radiotherapy, followed by tislelizumab, nab-paclitaxel, and carboplatin for 3 cycles. Surgery will be performed 4-6 weeks after the last neoadjuvant treatment.\n\nPrimary endpoint: Pathological Complete Response (pCR) rate. Secondary endpoints: Major Pathological Response (MPR) rate, Objective Response Rate (ORR), R0 resection rate, downstaging rate, 3-year Event-Free Survival (EFS), 3-year Overall Survival (OS), safety profile, and quality of life.\n\nApproximately 50 participants will be enrolled. Randomization will be stratified by tumor location, clinical T stage, and clinical N stage using a stratified block design via an EDC\u002FIWRS system.",[88],"Esophageal Squamous Cell Carcinoma (ESCC)",[90,91,92,93],"Esophageal Squamous Cell Carcinoma","Neoadjuvant Therapy","Short-Course Radiotherapy","PD-1 Inhibitor","2026-06-28",{"date":96,"type":40},"2026-07-01",{"date":98,"type":23},"2026-07-10",{"date":100,"type":23},"2029-06-30",{"name":46,"class":47},1,{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":18,"minAge":19,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":102},"100642960","anxiety-and-depression-in-ibs-a-brain-gut-axis-study-100642960","NCT07646834","Anxiety and Depression in IBS: A Brain-Gut Axis Study","Investigating the Brain-Gut Axis Regulatory Mechanism of Anxiety and Depression in Irritable Bowel Syndrome","Inclusion Criteria:\n\n1. Right-handed, aged 18-60 years, with more than 6 years of education;\n2. Meeting the Rome IV diagnostic criteria for IBS: Symptoms have been present for at least 6 months, and for the last 3 months, the following criteria are met: recurrent abdominal pain or discomfort, with symptoms occurring on at least 3 days per month in the last 3 months, associated with two or more of the following: 1) Improvement with defecation; 2) Onset associated with a change in frequency of stool; 3) Onset associated with a change in form (appearance) of stool;\n3. The following symptoms support the diagnosis of IBS: 1) Abnormal stool frequency: \\\u003C3 bowel movements per week or \\>3 bowel movements per day; 2) Abnormal stool form: lumpy\u002Fhard stool or mushy\u002Fwatery stool; 3) Straining during defecation; 4) Urgency or a feeling of incomplete evacuation; 5) Passage of mucus; 6) Bloating.\n\nExclusion Criteria:\n\n1. History of anti-anxiety\u002Fdepressant medication use (e.g., SSRI\u002FSNRI, Chinese patent medicines) within the past 1 month;\n2. History of antibiotic or probiotic use within the past 1 month;\n3. Other gastrointestinal diseases such as IBD, intestinal obstruction, or history of gastrointestinal surgery;\n4. Current or past history of psychiatric or neurological disorders, such as psychosis, brain tumors, or impaired consciousness;\n5. Concurrent severe hepatic or renal insufficiency, cardiovascular or cerebrovascular diseases, or malignant tumors; 7.0T MRI Contraindications: Presence of ferromagnetic implants (e.g., cardiac pacemakers, defibrillators, neurostimulators, aneurysm clips, cochlear implants, or any metallic foreign bodies); Non-ferromagnetic implants (e.g., titanium alloy, orthopedic implants), various types of intrauterine devices, various types of non-removable dentures (including dental implants); Presence of metallic foreign bodies (e.g., metal fragments, shrapnel, or filings in the eyes or body), such as in individuals engaged in welding work or with a history of metal item trauma; Tattoos or permanent makeup (e.g., eyebrows, lips) applied within the past month; Claustrophobia; Fever.\n\nHC Group Inclusion Criteria (all must be met):\n\n1. Right-handed, aged 18-60 years, with more than 6 years of education;\n2. All physiological indicators are within normal ranges, with no signs of disease;\n3. No family history of psychiatric or neurological disorders.",true,"60 Years",{"count":113,"type":23},200,"OBSERVATIONAL","This study aims to understand how the gut and the brain communicate in people with Irritable Bowel Syndrome (IBS) who also experience anxiety and depression. We want to see if changes in gut bacteria are linked to changes in brain function, and to find potential markers that could help in diagnosis or future treatments.\n\nWe are looking for two groups of volunteers aged 18 to 60 years: 1) 100 patients diagnosed with IBS who also have symptoms of anxiety or depression, and 2) 100 healthy volunteers for comparison. All participants must be right-handed.\n\nParticipants in this observational study will not receive any new drug or treatment. Instead, they will be asked to:\n\nComplete questionnaires about their bowel symptoms, anxiety, depression, sleep, and thinking skills.\n\nProvide a stool sample (about 5 grams) and a blood sample (about 5 ml).\n\nUndergo a brain scan using a 7 Tesla MRI machine, which will take about 45-50 minutes. They will need to lie still during the scan.\n\nSome IBS patients may be invited for a follow-up visit after 3 months to repeat the questionnaires and sample collection.\n\nThere are minimal risks involved. The MRI scan is non-radioactive and considered very safe, but some people may feel uncomfortable or claustrophobic inside the machine. Giving blood may cause brief pain, bruising, or, very rarely, infection. Your privacy is protected. All personal information and data will be coded and kept confidential, and will only be used for this research.\n\nThe main benefit to participants is receiving a detailed health assessment, including advanced brain imaging and analysis of gut bacteria, at no cost. There is no direct therapeutic benefit from participating, but the knowledge gained may help improve the understanding and future care of IBS.",[117,118,119],"Irritable Bowel Syndrome (IBS)","Anxiety","Depression","RECRUITING","2026-06-09",{"date":42,"type":40},{"date":124,"type":40},"2025-12-21",{"date":126,"type":23},"2027-12-30",{"name":46,"class":47},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":56,"minAge":19,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":139,"briefSummary":140,"conditions":141,"keywords":144,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100643090","phase-2-neoadjuvant-dalpiciclib--ai--shr-a1811-for-hrher2-low-breast-cancer-100643090","NCT07618923","Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+\u002FHER2-Low Breast Cancer","Dalpiciclib Combined With Aromatase Inhibitor (AI) Followed by SHR-A1811 as Neoadjuvant Therapy in Patients With Intermediate-to-High Risk HR+\u002FHER2-Low Breast Cancer: A Phase II Exploratory Study","TD-DASHER-01","Inclusion Criteria:\n\n1. Age ≥18 and ≤70 years\n2. Histologically confirmed invasive breast cancer, HR+ (ER ≥1% and\u002For PR ≥1%) and HER2-low (IHC 1+ or IHC 2+\u002FISH-)\n3. No prior systemic anti-tumor therapy for breast cancer\n4. Stage II-III (T1cN1-2M0, T2-4N0-2M0) per AJCC 8th edition\n5. At least one of the following intermediate-to-high risk factors:\n\n   * Axillary lymph node involvement ≥1\n   * Tumor size≥2 cm\n   * Grade 3 tumor\n   * Ki-67 ≥20%\n6. At least one measurable lesion per RECIST 1.1\n7. ECOG PS 0-1\n8. Adequate organ function (ANC ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL, Hb ≥90 g\u002FL, TBIL ≤1.5×ULN, ALT\u002FAST ≤2.5×ULN, Cr ≤1.5×ULN or CrCl ≥60 mL\u002Fmin, LVEF ≥50%, QTcF ≤470 ms in females, DLCO ≥50% predicted\n9. Negative pregnancy test (for women of childbearing potential) and agreement to use adequate contraception during and for 6 months after treatment\n10. Willing and able to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n1. Non-pathologically confirmed breast cancer\n2. Bilateral, inflammatory, or occult breast cancer\n3. Prior anticancer therapy (chemotherapy, radiotherapy, targeted therapy, endocrine therapy, etc.)\n4. Concurrent use of other anticancer treatments\n5. Other malignancy within 5 years (except cured basal cell carcinoma or cervical carcinoma in situ)\n6. Participation in another interventional clinical trial within 4 weeks prior to first dose\n7. Use of immunosuppressive agents or systemic corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) within 2 weeks prior to first dose\n8. Live or attenuated vaccine within 4 weeks prior to first dose\n9. Major surgery unrelated to breast cancer within 4 weeks prior to first dose\n10. Active or history of autoimmune disease requiring systemic treatment\n11. Known immunodeficiency (e.g., HIV positivity) or history of organ transplantation\n12. Uncontrolled or significant cardiovascular disease (e.g., NYHA class III\u002FIV heart failure, myocardial infarction, unstable angina, arrhythmia requiring treatment, QTcF \\>470 ms, uncontrolled hypertension)\n13. Known or suspected interstitial lung disease (ILD) or significant pre-existing pulmonary disease\n14. Active hepatitis B (HBsAg positive and HBV DNA ≥500 IU\u002FmL) or hepatitis C (HCV RNA above ULN), cirrhosis, or uncontrolled severe infection\n15. Known bleeding or thrombotic tendency\n16. Allergy or contraindication to any study drug or excipient\n17. Pregnancy, breastfeeding, or positive pregnancy test at baseline\n18. Any concurrent condition that may compromise patient safety or study compliance (e.g., uncontrolled hypertension, severe diabetes, active infection)\n19. History of neurological or psychiatric disorders (e.g., epilepsy, dementia) or any condition deemed unsuitable by the investigator.","70 Years",{"count":138,"type":23},20,[85],"This is a phase II, single-arm, prospective exploratory study to evaluate the efficacy and safety of neoadjuvant dalpiciclib (a CDK4\u002F6 inhibitor) plus an aromatase inhibitor (AI) followed by SHR-A1811 (an anti-HER2 antibody-drug conjugate) in patients with intermediate-to-high risk, hormone receptor-positive (HR+), HER2-low breast cancer. Patients will receive dalpiciclib (125 mg orally once daily, days 1-21, every 4 weeks) plus AI (anastrozole 1 mg, letrozole 2.5 mg, or exemestane 25 mg once daily) for 4 cycles, followed by SHR-A1811 (4.8 mg\u002Fkg intravenously every 3 weeks) for 4 cycles. The primary endpoint is objective response rate (ORR) per RECIST 1.1. Secondary endpoints include pathological complete response (pCR), breast-conserving surgery rate, event-free survival (EFS), change in Ki-67 index, and safety. A total of 20 participants will be enrolled.",[142,143],"Breast Cancer","HR Positive\u002FHER2 Low Breast Cancer",[142,145,146,91,147,148],"HR-positive","HER2-low","Dalpiciclib","SHR-A1811","2026-06-08",{"date":151,"type":40},"2026-06-11",{"date":153,"type":23},"2026-06",{"date":155,"type":23},"2029-01",{"name":46,"class":47},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":164,"targetDuration":4,"studyType":24,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},"100525939","clinical-study-of-taurine-combined-with-neoadjuvant-chemo-immunotherapy-for-treatment-of-locally-advanced-gastric-cancer-100525939","NCT06128252","Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer","A Prospective, Multicentre, Double-blind Randomized Controlled Clinical Study of the Efficacy and Safety of Taurine Combined With Serplulimab and Chemotherapy Versus Serplulimab Combined With Chemotherapy for Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Age 18-75 years old, no gender limitation;\n2. Pathologically confirmed gastric or gastroesophageal junction adenocarcinoma with cTNM stage II\u002FIII，T≥3, N ≥0, M=0；\n3. Expected survival of ≥ 3 months;\n4. The tumor specimens were PD-L1 positive (CPS ≥ 1)；\n5. There is a measurable lesion with the possibility of radical R0 resection after evaluation by doctors；\n6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n7. Patients informed about the purpose and course of the study and provided a written consent to participate.\n\nExclusion Criteria:\n\n1. Use of taurine agent within 1 month prior to the first dose of study treatment and throughout the study;\n2. Patients with positive HER-2；\n3. Patients with gastrointestinal obstruction or active bleeding in the gastrointestinal tract, as well as perforation and dysphagia;\n4. Patients with severe heart, lung, liver, kidney, endocrine, hematopoietic system or psychiatric diseases were considered not suitable for the study group;\n5. Human immunodeficiency virus (HIV) infection or known acquired immune deficiency syndrome (AIDS) or autoimmune disease or immunosuppressant use；\n6. There are patients who may increase the risk of participating in the study and study medication, or other severe, acute and chronic diseases, and are not suitable for participating in the clinical study according to the judgment of the investigator.",{"count":165,"type":23},96,[62],"This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (serplulimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer patient outcomes than with serplulimab and chemotherapy alone.",[169],"Gastric Cancer",[171,172],"Taurine","neoadjuvant immunotherapy and chemotherapy",{"date":121,"type":40},{"date":175,"type":40},"2024-09-01",{"date":177,"type":23},"2027-06-30",{"name":46,"class":47},15,{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":110,"sex":56,"minAge":57,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":102},"100639747","clinical-value-of-saline-infusion-sonohysterography-in-the-assessment-of-cesarean-scar-defects-100639747","NCT07610668","Clinical Value of Saline Infusion Sonohysterography in the Assessment of Cesarean Scar Defects","Preliminary Clinical Application Study of Saline Infusion Onohysterography in Structure of Cesarean Scar Surgery","Inclusion Criteria:\n\n* More than 6 months after cesarean delivery;\n* Presenting with clinical symptoms-including abnormal uterine bleeding, dysmenorrhea, prolonged menstrual spotting, or secondary infertility;\n* Requiring saline infusion sonohysterography (SIS) to evaluate the cesarean scar.\n\nExclusion Criteria:\n\n* Multiple cesarean deliveries;\n* Patients contraindicated for saline infusion sonohysterography (SIS), including pregnancy or suspected pregnancy, failure to meet vaginal hygiene criteria, inability to cooperate during the procedure, or suboptimal image quality;\n* Cases with incomplete clinical data or lost to follow-up.","50 Years",{"count":189,"type":23},300,"This study selected patients who underwent cesarean section and were scheduled to undergo Saline Infusion Sonohysterography (SIS) for evaluating the structure of the incision. Clinical characteristics and clinical symptoms were collected. Combined with hysteroscopy, MRI, conventional ultrasound and SIS examination results, the study analyzed the detection rate of cesarean section diverticula by SIS, the changes in diverticulum size and the diagnostic efficacy of residual muscle layer thickness at the incision site. The surgical methods and clinical symptom improvement of patients with CSD after surgery were followed up for half a year to one year. The study aimed to clarify the guiding value of SIS in clinical decision-making and patient prognosis for patients, and to analyze the etiological relationship between the true incidence of CSD and clinical complications. Thus, it provided evidence-based basis for clinical events of cesarean section surgery → CSD → CSD complications → surgical treatment of CSD → patient prognosis, promoting the progress of precise diagnosis and treatment of female reproductive health.",[192],"Infertility",[194,195,196,197],"Saline Infusion Sonohysterography","Transvaginal ultrasonography","Cesarean scar diverticulum","Residual myometrial thickness","2026-05-26",{"date":200,"type":40},"2026-05-28",{"date":202,"type":40},"2023-01-01",{"date":204,"type":23},"2026-07-31",{"name":46,"class":47},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":213,"targetDuration":4,"studyType":24,"phases":215,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":102},"100637451","phase-2-retlirafusp-alfa-plus-chemotherapy-as-neoadjuvant-therapy-for-thoracic-escc-100637451","NCT07618910","Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC","A Prospective, Single-Arm, Exploratory Study of Retlirafusp Alfa Combined With Chemotherapy as Neoadjuvant Therapy for Thoracic Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Voluntarily signed and dated written informed consent to participate in this study.\n2. Histologically or cytologically confirmed esophageal squamous cell carcinoma (ESCC).\n3. Clinically staged as thoracic ESCC evaluated by CT, MRI, or endoscopic ultrasonography (EUS), with a clinical stage of T1b-4aN+M0 or T2-4N0M0 according to the American Joint Committee on Cancer (AJCC) 8th edition. For T2N0 patients, at least one high-risk factor must be present: lymphovascular invasion (LVI), tumor size \\>= 3 cm, or poor differentiation.\n4. Anticipated to achieve an R0 resection.\n5. Age between 18 and 75 years (inclusive) at the time of signing the informed consent, of either sex.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, or surgery.\n8. Planned to undergo definitive surgical resection following the completion of neoadjuvant therapy.\n9. No contraindications to surgical resection.\n10. Adequate major organ functions, meeting the following laboratory criteria: 10a) Hematology (no blood components, cell growth factors, leukogenic agents, platelet-stimulating agents, or anemia-correcting therapies allowed within 14 days prior to the first dose of study drug): Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\u002FL; Platelet count \\>= 100 x 10\\^9\u002FL; Hemoglobin \\>= 90 g\u002FL. 10b) Blood Biochemistry: Total bilirubin (TBIL) \\\u003C= 1.5 x Upper Limit of Normal (ULN); Alanine aminotransferase (ALT) \\\u003C= 2.5 x ULN; Aspartate aminotransferase (AST) \\\u003C= 2.5 x ULN; Serum creatinine \\\u003C= 1.5 x ULN, or creatinine clearance (CrCl) \\>= 50 mL\u002Fmin. 10c) Coagulation Function: International Normalized Ratio (INR) \\\u003C= 1.5 x ULN; Activated Partial Thromboplastin Time (APTT) \\\u003C= 1.5 x ULN.\n11. Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study drug and agree to use highly effective methods of contraception (e.g., intrauterine device \\[IUD\\], contraceptives, or condoms) during the trial and for at least 3 months after the last dose. Male subjects whose partners are females of childbearing potential must be surgically sterile or agree to use highly effective contraception during the trial and for at least 3 months after the last dose.\n12. Good compliance and willingness to cooperate with the scheduled follow-up visits.\n\nExclusion Criteria:\n\n1. Tumors with clear invasion into adjacent organs of the esophageal lesion (e.g., aorta or trachea).\n2. Presence of supraclavicular lymph node metastasis.\n3. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage.\n4. Poor nutritional status with Body Mass Index (BMI) \\\u003C 18.5 kg\u002Fm2; however, patients whose nutritional status is corrected after symptomatic nutritional support before enrollment may still be considered after evaluation by the principal investigator.\n5. Known history of hypersensitivity to the study drugs.\n6. Prior or current receipt of any of the following treatments: 6a) Any prior anti-tumor radiotherapy, chemotherapy, or other anti-tumor medications. 6b) Use of immunosuppressive medications or systemic corticosteroid therapy for immunosuppressive purposes (dose \\> 10 mg\u002Fday of prednisone or equivalent dose) within 2 weeks prior to the first dose of study drug. 6c) Receipt of live attenuated vaccines within 4 weeks prior to the first dose of study drug. 6d) Major surgery or severe trauma within 4 weeks prior to the first dose of study drug.\n7. Active autoimmune disease or a history of autoimmune disease, including but not limited to: interstitial lung disease, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism (subjects stable on hormone replacement therapy can be considered for inclusion). Subjects with psoriasis or childhood asthma\u002Fallergies that have completely resolved without any adult intervention may be considered for inclusion; however, patients requiring medical intervention with bronchodilators are excluded.\n8. History of immunodeficiency, including positive HIV test, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation.\n9. Uncontrolled clinical cardiac symptoms or diseases, including but not limited to: (1) New York Heart Association (NYHA) Class II or higher heart failure, (2) unstable angina, (3) myocardial infarction within the past 1 year, (4) clinically significant supraventricular or ventricular arrhythmias that are uncontrolled or poorly controlled despite clinical intervention.\n10. Severe infection (CTCAE \\> Grade 2) within 4 weeks prior to the first dose of study drug, such as severe pneumonia, bacteremia, or infectious complications requiring hospitalization; baseline chest imaging indicating active pulmonary inflammation, signs or symptoms of infection within 14 days prior to the first dose of study drug, or requiring oral or intravenous antibiotic therapy (except for prophylactic antibiotic use).\n11. Active tuberculosis infection detected by medical history or CT scan, or a history of active tuberculosis infection within 1 year prior to enrollment, or a history of active tuberculosis infection more than 1 year ago without formal standard treatment.\n12. Screening imaging showing tumor encasement of major blood vessels or significant necrosis\u002Fcavitation, where the investigator judges that study participation would pose a high risk of hemorrhage.\n13. Active hepatitis B (HBV DNA \\>= 2000 IU\u002FmL or 10\\^4 copies\u002FmL), or hepatitis C (HCV antibody positive and HCV RNA above the lower limit of detection of the assay).\n14. Diagnosis of other malignant tumors within 5 years prior to the first dose of study drug, unless the malignancy carries a low risk of metastasis or death (5-year survival rate \\> 90%), such as adequately treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ.\n15. Pregnant or lactating females.\n16. Any other factors that, in the judgment of the investigator, may compel premature termination of study participation, such as other severe medical or psychiatric conditions requiring concomitant therapy, alcohol abuse, drug abuse, familial or social factors, or any other conditions that may compromise subject safety or compliance.",{"count":214,"type":23},33,[85],"This is a prospective, single-arm, exploratory clinical study designed to evaluate the efficacy and safety of retlirafusp alfa combined with chemotherapy (nab-paclitaxel and cisplatin) as a neoadjuvant therapy for patients with resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC).\n\nThe primary objective of this study is to assess the pathologic complete response (pCR) rate in the target population. A total of 33 patients with histologically or cytologically confirmed resectable locally advanced thoracic ESCC are planned to be enrolled.",[90],[219,220,221],"ESCC","Retlirafusp alfa","Neoadjuvant","2026-05-24",{"date":224,"type":40},"2026-06-01",{"date":226,"type":23},"2026-05-30",{"date":228,"type":23},"2028-05-30",{"name":46,"class":47},{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":237,"targetDuration":4,"studyType":24,"phases":239,"briefSummary":240,"conditions":241,"keywords":242,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":102},"100627743","phase-2-time-of-day-of-immunotherapy-infusion-in-neoadjuvant-immunochemotherapy-for-thoracic-escc-100627743","NCT07452601","Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC","Effect of Time-of-Day of Immunotherapy Infusion on Outcomes of Neoadjuvant Immunochemotherapy in Thoracic Esophageal Squamous Cell Carcinoma: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Patients who have signed a written informed consent form and voluntarily agree to participate in the study.\n2. Histologically or cytologically confirmed esophageal squamous cell carcinoma.\n3. Tumor located in the thoracic esophagus, assessed by CT, MRI, EUS, or other imaging modalities, with clinical stage T1b-4aN+M0 or T2-4N0M0 (T2N0 patients must have high-risk features: lymphovascular invasion \\[LVI\\], tumor ≥3 cm, or poor differentiation) according to AJCC 8th edition.\n4. Tumors deemed potentially resectable with R0 margins.\n5. Age between 18 and 75 years, male or female.\n6. ECOG performance status of 0 or 1.\n7. No prior anti-tumor treatment for esophageal cancer, including surgery, radiotherapy, or chemotherapy.\n8. Planned to undergo surgery after completion of neoadjuvant therapy.\n9. No contraindications to surgery.\n10. Adequate organ function, including:\n\n    1. Hematologic parameters(no blood products, growth factors, erythropoiesis-stimulating agents, or platelet-stimulating drugs within 14 days prior to first study drug administration): Absolute neutrophil count ≥1.5 × 10⁹\u002FL;Platelet count ≥100 × 10⁹\u002FL;Hemoglobin ≥90 g\u002FL.\n    2. Biochemical parameters:Total bilirubin ≤1.5 × ULN; ALT ≤2.5 × ULN, AST ≤2.5 × ULN;Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL\u002Fmin.\n    3. Coagulation parameters:International normalized ratio (INR) ≤1.5 × ULN; Activated partial thromboplastin time (APTT) ≤1.5 × ULN.\n11. For women of childbearing potential, a negative serum pregnancy test within 72 hours prior to first study drug administration and agreement to use effective contraception during the study and for at least 3 months after the last dose (e.g., intrauterine device, oral contraceptives, or condoms). Male participants with partners of childbearing potential must be surgically sterilized or agree to use effective contraception during the study and for at least 3 months after the last dose.\n12. Good compliance and willingness to adhere to study procedures and follow-up. ---\n\nExclusion Criteria:\n\n1. Tumor with obvious invasion of adjacent critical structures, such as the aorta or trachea.\n2. Presence of supraclavicular lymph node metastasis.\n3. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.\n4. Poor nutritional status with body mass index (BMI) \\\u003C18.5 kg\u002Fm²; patients whose nutritional status is corrected before randomization through supportive care may be considered eligible at the discretion of the principal investigator.\n5. Known hypersensitivity to monoclonal antibodies, adebrelimab, nab-paclitaxel, cisplatin, or other platinum-based agents.\n6. Prior or ongoing treatments as follows:\n\n   1. Any prior anti-tumor therapy, including chemotherapy, radiotherapy, or other anti-cancer drugs;\n   2. Use of systemic immunosuppressive therapy or corticosteroids for immunosuppression (\\>10 mg\u002Fday prednisone or equivalent) within 2 weeks prior to first study drug administration. Inhaled or local steroid use and corticosteroid replacement therapy \\>10 mg\u002Fday prednisone equivalent in patients without active autoimmune disease are permitted;\n   3. Administration of live attenuated vaccines within 4 weeks prior to first study drug administration;\n   4. Major surgery or severe trauma within 4 weeks prior to first study drug administration.\n7. Active autoimmune disease or history of autoimmune disease, including but not limited to interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism (patients on stable hormone replacement therapy may be eligible). Patients with psoriasis or childhood asthma\u002Fallergy fully resolved in adulthood and not requiring intervention may be eligible, but those requiring ongoing medical management with bronchodilators are excluded.\n8. History of immunodeficiency, including positive HIV test, other congenital or acquired immunodeficiency, or history of organ or allogeneic bone marrow transplantation.\n9. Uncontrolled clinically significant cardiac conditions, including but not limited to:\n\n   NYHA class II or higher heart failure;Unstable angina;Myocardial infarction within 1 year;Clinically significant supraventricular or ventricular arrhythmias inadequately controlled despite intervention.\n10. Severe infection (CTCAE \\> grade 2) within 4 weeks prior to first study drug administration requiring hospitalization, including severe pneumonia, bacteremia, or infectious complications. Patients with active pulmonary inflammation on baseline imaging, infection symptoms within 14 days prior to first study drug administration, or requiring oral\u002FIV antibiotics (excluding prophylactic antibiotics) are excluded.\n11. Active pulmonary tuberculosis, history of active tuberculosis within 1 year prior to enrollment, or history of untreated active tuberculosis more than 1 year prior to enrollment.\n12. Active hepatitis B (HBV DNA ≥2000 IU\u002FmL or 10⁴ copies\u002FmL) or hepatitis C infection (positive HCV antibody with HCV RNA above the assay detection limit).\n13. Diagnosis of other malignancies within the past 5 years, except for tumors with low risk of metastasis or mortality (5-year survival \\>90%), such as adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ.\n14. Pregnant or breastfeeding women.\n15. Any other condition that, in the opinion of the investigator, could lead to premature discontinuation of study treatment or compromise participant safety or compliance, including serious comorbidities (including psychiatric disorders requiring concomitant therapy), alcohol or substance abuse, or social\u002Ffamilial factors.",{"count":238,"type":23},90,[85],"This is a prospective, multi-cohort, exploratory clinical study designed to evaluate the efficacy and safety of neoadjuvant adebrelimab combined with chemotherapy in patients with resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), with a particular focus on the effect of the time-of-day of immunotherapy infusion.\n\nEligible patients with histologically or cytologically confirmed, resectable locally advanced thoracic ESCC will be randomly assigned in a 1:1:1 ratio to three cohorts according to predefined immunotherapy infusion time windows. Cohort A will receive adebrelimab plus chemotherapy with the first cycle initiated at or after 15:00 and subsequent cycles initiated before 15:00; Cohort B will receive all three cycles initiated before 15:00; and Cohort C will receive all three cycles initiated at or after 15:00. Neoadjuvant treatment consists of three cycles of adebrelimab in combination with nab-paclitaxel and cisplatin, followed by surgical resection 4-6 weeks after completion of neoadjuvant therapy.\n\nThe primary endpoint of the study is pathological complete response (pCR). Secondary endpoints include event-free survival (EFS), major pathological response (MPR) rate, R0 resection rate, overall survival (OS), and disease-free survival (DFS).\n\nTumor response will be assessed according to RECIST version 1.1, and pathological response will be evaluated using the College of American Pathologists (CAP) tumor regression grading system and AJCC 8th edition staging criteria. Safety will be continuously monitored throughout the study, and patients will undergo scheduled follow-up for disease progression or recurrence and survival after completion of study treatment.",[90],[219,243,221,244],"Time-of-Day","Adebrelimab",{"date":200,"type":40},{"date":247,"type":40},"2026-05-05",{"date":249,"type":23},"2028-12-30",{"name":46,"class":47},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":18,"minAge":258,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":24,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":274,"leadSponsor":276,"locationsCount":102},"100637853","phase-2-serplulimab-monotherapy-in-elderly-patients-with-nsclc-and-pd-l1-tps--50-100637853","NCT07596121","Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%","Multicenter, Single-arm, Phase II Exploratory Study of Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%","Inclusion Criteria:\n\n* 1.Voluntary participation and informed consent: Subjects must voluntarily join the study, sign the written informed consent form (ICF), and demonstrate good compliance.\n\n  2.Age and Gender: Aged ≥65 years at the time of signing the ICF, regardless of gender.\n\n  3.Diagnosis and Staging: Histologically or cytologically confirmed Stage IIIB (ineligible for definitive chemoradiotherapy), Stage IIIC, or Stage IV NSCLC according to the AJCC 8th edition staging system.\n\n  4.PD-L1 Expression: Tumor tissue confirmed as PD-L1 TPS≥50% by a central laboratory or a validated local laboratory, using SP263 or 22C3 assays (a formal test report must be provided).\n\n  5.Driver Gene Status: Known absence of actionable driver mutations, including but not limited to EGFR sensitive mutations, ALK fusions, and ROS1 fusions.\n\n  6.Measurable Disease: At least one measurable target lesion per RECIST v1.1 criteria (lesions must not have received prior radiotherapy).\n\n  7.Prior Treatment History: No prior systemic therapy for advanced or metastatic disease. For patients who received adjuvant or neoadjuvant chemotherapy, inclusion is permitted if disease recurrence occurred ≥6 months after the completion of the last dose.\n\n  8.Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-2.\n\n  9.Adequate organ and bone marrow function (no blood transfusions or hematopoietic stimulating factor therapy within 14 days prior to the first dose):\n  * Absolute Neutrophil Count (ANC)≥1.5 x 10\\^9\u002F\u002FL\n  * Platelet Count (PLT)≥100 x 10\\^9\u002F\u002FL\n  * Hemoglobin (Hb)≥90 g\u002FL\n  * Serum Creatinine (Cr) ≤ 1.5 x Limit of Normal (ULN) or Creatinine Clearance ≥ 50mL\u002Fmin\n  * Total Bilirubin (TBIL) ≤ 1.5 x ULN\n  * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)≤ 2.5 x ULN(≤ 5 x ULN for patients with liver metastases)\n\nExclusion Criteria:\n\n* 1\\. Hypersensitivity: Known hypersensitivity to serplulimab or any of its excipients.\n\n  2\\. Prior Immunotherapy: Prior treatment with any anti-PD-1, anti-PD-L1, anti-CTLA-4, or other immune checkpoint inhibitors (ICIs).\n\n  3\\. Autoimmune Disease: Active autoimmune disease requiring systemic treatment (e.g., corticosteroids or immunosuppressants) within the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency) is permitted.\n\n  4\\. Lung Disease\u002FPneumonitis: Active interstitial lung disease (ILD) or pneumonitis, or a history of (non-infectious) pneumonitis requiring steroid treatment.\n\n  5\\. Infections: Active infection requiring systemic therapy. 6. CNS Metastases: Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. However, patients with treated (via surgery or radiotherapy) and stable brain metastases are eligible, provided they are radiographically stable for at least 4 weeks prior to the first dose, have no evidence of new or enlarged brain lesions, and have discontinued glucocorticoids for at least 14 days.\n\n  7\\. Pregnancy and Breastfeeding: Pregnant or breastfeeding women. 8. Investigator Discretion: Any other condition that, in the investigator's opinion, may interfere with the evaluation of the study drug, jeopardize subject safety, or confound the interpretation of study results.","65 Years",{"count":260,"type":23},60,[85],"This prospective clinical study aims to evaluate and observe the efficacy and safety of Serplulimab Monotherapy in Elderly Patients with NSCLC and PD-L1 TPS ≥ 50% using a multicenter, single-arm, phase II design.\n\nThe study is planned to be conducted in Shaanxi Province, China, with an initial target enrollment of 60 patients. The study commenced in May 2026, and recruitment is expected to conclude around May 2026, with the trial anticipated to end by May 2027.\n\nAssuming no occurrences such as withdrawal of informed consent by subjects, intolerable adverse drug reactions, or investigator-assessed unsuitability for further participation, each participant's estimated duration of study treatment will continue until radiographically confirmed tumor progression.",[264],"NSCLC (Non-small Cell Lung Cancer)",[266,267,268,269],"NSCLC","Serplulimab","PD-L1 TPS≥50%","Monotherapy","2026-05-13",{"date":272,"type":40},"2026-05-19",{"date":270,"type":40},{"date":275,"type":23},"2027-05-31",{"name":46,"class":47},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":285,"targetDuration":4,"studyType":24,"phases":287,"briefSummary":288,"conditions":289,"keywords":293,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":304,"locationsCount":102},"100600048","effect-of-semi-elemental-enteral-nutrition-on-gastrointestinal-tolerance-in-patients-with-traumatic-brain-injury-100600048","NCT07092423","Effect of Semi-elemental Enteral Nutrition on Gastrointestinal Tolerance in Patients With Traumatic Brain Injury.","The Effect of Semi-elemental Enteral Nutrition on Gastrointestinal Tolerance in Patients With Traumatic Brain Injury: a Randomized Exploratory Study","SEMINAR","Inclusion Criteria:\n\n* Aged 18-75 years;\n* Clinically diagnosed with closed traumatic brain injury;\n* Glasgow Coma Scale (GCS) score ≤ 8;\n* Ability to initiate enteral nutrition within 48 hours post-injury;\n* Expected need for enteral nutrition support ≥3 days based on clinical assessment (Nutritional Risk Screening 2002 \\[NRS2002\\] score ≥3).\n\nExclusion Criteria:\n\n* GCS=3 with bilateral fixed and dilated pupils;\n* Hemodynamic instability or respiratory failure: mean arterial pressure \\\u003C70mmHg, PaO2\u002FFiO2\\\u003C150, PaCO2\\\u003C30 mmHg or \\>45 mmHg, or lactate \\>5 mmol\u002Fl;\n* Contraindications to both nasogastric and nasojejunal tube placement, or inability to complete tube placement within 48 hours of onset;\n* Contraindications to enteral nutrition therapy or semi-recumbent positioning;\n* Pre-existing intellectual disability or physical disability affecting outcome assessment;\n* Gastrointestinal abnormalities likely to affect gastrointestinal function, such as short bowel syndrome (defined as total small bowel length ≤122 cm), ulcerative colitis, Crohn's disease, or any form of ostomy;\n* Body mass index (BMI) \\\u003C18kg\u002Fm2;\n* Concomitant abdominal injury or extracranial injury with AIS score \\>3 in any region;\n* Presence of malignancy, severe cardiac insufficiency (ejection fraction \\\u003C50%), severe hepatic failure (Child-Pugh score ≥7), or severe renal failure (glomerular filtration rate ≤30 mL\u002Fmin or serum creatinine ≥4mg\u002FdL) at NICU admission;\n* Concurrent severe disease with expected survival ≤14 days;\n* Pregnancy, within 30 days postpartum, or breastfeeding;\n* Refusal of treatment or receipt of palliative care;\n* Patient or family declines informed consent;\n* Current participation in another interventional clinical trial.",{"count":286,"type":23},100,[62],"Study Objective This clinical trial primarily aims to investigate whether semi-elemental enteral nutrition (SEN) improves gastrointestinal tolerance in patients with severe traumatic brain injury (TBI) and to evaluate its impact on clinical outcomes. The safety profile of SEN will also be assessed.\n\nKey Research Questions Does SEN reduce the incidence of acute gastrointestinal injury (AGI) in severe TBI patients?\n\nStudy Design\n\nParticipants will be randomized 1:1 into either:\n\nIntervention group: Receives SEN initiated within 48 hours post-injury and continued for ≥7 days.\n\nControl group: Receives standard enteral nutrition over the same period.",[290,291,292],"Traumatic Brain Injury","Neurocritical Care","Enteral Feeding Intolerance",[290,294,295,296,291,297],"Enteral Nutrition","Gastrointestinal Intolerance","Semi-elemental Formula","Prognosis","2026-04-26",{"date":300,"type":40},"2026-04-30",{"date":302,"type":40},"2025-05-18",{"date":275,"type":23},{"name":46,"class":47},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":24,"phases":314,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":4},"100634324","phase-1-vebectotamab-vedotin-combined-with-pucotelimab-in-the-treatment-of-locally-advanced-laryngeal-carcinoma-100634324","NCT07538206","Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma","An Exploratory Study of Neoadjuvant Vibecortamab Combined With Putilimab in Locally Advanced Laryngeal Cancer - A Single-Arm, Phase II Study","Inclusion Criteria:\n\n1. Aged 18 to 80 years old (inclusive of 18 and 80 years), of either gender.\n2. Histopathologically or cytologically confirmed, and diagnosed as resectable locally advanced laryngeal carcinoma by MRI imaging.3.At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.4. Male subjects are eligible if they agree to comply with the following standards during treatment and for at least 180 days after the last cycle of chemotherapy:a) Prohibition of sperm donation;AND• Abstain from heterosexual intercourse as a usual and preferred lifestyle (long-term and persistent abstinence) and agree to maintain abstinence;OR• Agree to use contraceptive measures unless confirmed as azoospermic (vasectomy or secondary to medical reasons, see Appendix 5), with details as follows:→ Use a male condom during penile-vaginal intercourse with a reproductive-aged female partner who is not currently pregnant, and the partner uses an additional contraceptive method.Note: Males whose partners are pregnant or breastfeeding must agree to either maintain abstinence from penile-vaginal intercourse at all times or use a male condom for every penile-vaginal penetration.b) Male subjects must also agree to use a male condom during any activity that allows ejaculation with others of any gender.c) Contraceptive methods used by males must comply with regulations regarding contraception in clinical research participation.5.Female subjects are eligible if they are not pregnant or breastfeeding, and meet at least one of the following conditions:(1) Not a woman of childbearing potential (WOCBP);OR(2) If a WOCBP, use a highly effective contraceptive method (annual failure rate \\\u003C1%) with low user dependence, or abstain from heterosexual intercourse as a preferred and regular lifestyle (long-term and persistent abstinence) during the intervention period and for at least 210 days after the last cycle of chemotherapy, and agree not to donate ova (eggs, oocytes) to others or freeze\u002Fstore ova for personal reproductive purposes during this period. Investigators shall evaluate the likelihood of contraceptive method failure (i.e., non-compliance, recent initiation) relative to the first administration of study treatment.a) WOCBP must have a negative result on a highly sensitive urine or serum pregnancy test (urine or serum test selected per regulatory requirements) within 24 hours (urine) or 72 hours (serum) before the first administration of study treatment to be enrolled.Note: If the interval between the screening pregnancy test and the first administration of study intervention exceeds 24 hours (urine) or 72 hours (serum), a repeat pregnancy test (urine or serum) must be performed, and the result must be negative for the subject to start receiving study medication.b) If a urine test is inconclusive (e.g., unclear result), a serum pregnancy test is required. In such cases, subjects with a positive serum pregnancy test result must be excluded.c) Investigators are responsible for reviewing medical history, menstrual history, and recent sexual activity to reduce the risk of enrolling women with undetected early pregnancy.d) Contraceptive methods used by females must comply with regulations regarding contraception in clinical research participation;6.Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2 within 3 days before the first administration of study intervention.7.Evidence of extranodal extension (ENE) in lymph nodes (confirmed by MRI, CT, or pathology).8.Voluntarily sign the written informed consent form for the study.9.Expected survival time ≥6 months.10.Adequate organ function as indicated by screening laboratory test results.a) Hematological parameters:White blood cell (WBC) count ≥4 × 10⁹\u002FL;Absolute neutrophil count (ANC) ≥1.5 × 10⁹\u002FL;Platelet count ≥100 × 10⁹\u002FL;Hemoglobin (Hb) ≥90 g\u002FL;b) Renal function:Serum creatinine ≤1.5 × upper limit of normal (ULN), or creatinine clearance (CrCl) \\>60 mL\u002Fmin (calculated using the Cockcroft-Gault formula):Female: CrCl = \\[(140 - age) × body weight (kg) × 0.85\\] \u002F (72 × Scr \\[mg\u002FdL\\])Male: CrCl = \\[(140 - age) × body weight (kg) × 1.00\\] \u002F (72 × Scr \\[mg\u002FdL\\])c) Hepatic function:Serum total bilirubin ≤1.5 × ULN;Aspartate aminotransferase (AST) ≤2.5 × ULN;Alanine aminotransferase (ALT) ≤2.5 × ULN;d) Coagulation function:International Normalized Ratio (INR) ≤1.5;Prothrombin time (PT) or activated partial thromboplastin time (APTT) ≤1.5 × ULN.11.Good compliance and willingness to cooperate with follow-up procedures.\n\nExclusion Criteria:\n\n1. Prior systemic therapy for advanced (metastatic) or unresectable (locally advanced) laryngeal cancer, except for permitted neoadjuvant\u002Fadjuvant therapy. Neoadjuvant\u002Fadjuvant therapy must have been completed at least 6 months before the diagnosis of advanced and\u002For unresectable disease. Subjects who received prior neoadjuvant\u002Fadjuvant therapy and had R2 pathology after tumor resection are excluded.\n2. Active autoimmune disease requiring systemic therapy (i.e., disease-modifying agents, corticosteroids, or immunosuppressive drugs) within the past 2 years. Replacement therapies (e.g., thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency) are not considered systemic therapy and are permitted.3.Major surgery prior to the initiation of study intervention with inadequate recovery from surgery and\u002For surgical complications.4.Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or drugs targeting other stimulatory or co-inhibitory T-cell receptors (e.g., CTLA-4, OX-40, CD137).5.Prior treatment with EGFR-targeted agents.6.Anti-tumor therapy for advanced tonsillar cancer, including investigational drugs, within 4 weeks before enrollment.7.Unresolved adverse events (AEs) from prior anti-cancer therapy (i.e., AEs \\> Grade 1 or baseline). Subjects with neuropathy ≤ Grade 2 may be eligible based on investigator assessment.8.Radiotherapy within 2 weeks before the start of investigational treatment. Subjects must have recovered from all radiotherapy-related toxicities, be free of corticosteroid use, and have no history of radiation pneumonitis. A 1-week washout period is permitted for palliative radiotherapy (≤2 weeks of radiotherapy) for non-central nervous system (CNS) disease (if deemed safe by the investigator). A 2-week washout period is required for longer radiotherapy courses (\\>2 weeks).9.Administration of live vaccines within 30 days before the first dose of study drug.Note: Live vaccines include, but are not limited to: measles, mumps, rubella, varicella\u002Fzoster (chickenpox), yellow fever, rabies, bacillus Calmette-Guérin (BCG), and typhoid vaccines. Seasonal influenza vaccines administered by injection are generally inactivated virus vaccines and are permitted; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not permitted.10.Current or prior participation in a study of an investigational drug, or use of an investigational device within 4 weeks before the first dose of study drug.Note: Subjects who have entered the follow-up phase of an investigational study are eligible to participate in this study if at least 4 weeks have passed since the last dose of the prior investigational drug.11.Diagnosis of immunodeficiency or receipt of long-term systemic corticosteroid therapy (dose exceeding 10 mg prednisone equivalent per day) or any form of immunosuppressive therapy within 7 days before the first dose of study drug.12.History of another invasive malignancy that is progressive or required active treatment within the past 3 years.Note: Subjects with a history of skin basal cell carcinoma, skin squamous cell carcinoma, or carcinoma in situ (e.g., ductal carcinoma in situ of the breast, cervical carcinoma in situ) who have received potentially curative treatment are not excluded.13.Severe hypersensitivity reaction (\\> Grade 3) to toripalimab, nimotuzumab, albumin-bound paclitaxel, carboplatin, and\u002For any of their excipients.14.History of (non-infectious) pneumonitis requiring corticosteroid therapy, or current pneumonitis.15.Active infection requiring systemic therapy.16.Known history of human immunodeficiency virus (HIV) infection.17.Known active tuberculosis (TB; Mycobacterium tuberculosis).18.Severe, poorly controlled concurrent diseases (e.g., heart failure, diabetes mellitus, hypertension, liver failure, renal failure, thyroid disease, psychiatric illness, etc.).19.Major surgery within 30 days before the first dose of investigational drug or planned surgery during the study period.20.Inappropriate for study participation as assessed by the investigator.21.Unwillingness to participate in the study or inability to sign the informed consent form.22.Known history or any evidence of central nervous system (CNS) metastases and\u002For carcinomatous meningitis as assessed by the study site investigator.23.History or evidence of disease, treatment, or abnormal laboratory values that may interfere with trial results, prevent full participation in the study (e.g., hearing impairment), or that the investigator believes would not be in the subject's best interest to participate.24.Known psychiatric illness or substance abuse disorder that would interfere with the subject's ability to comply with study requirements.25.History of allogeneic tissue\u002Fsolid organ transplantation.","80 Years",{"count":48,"type":23},[315,85],"PHASE1","This is a prospective, single-arm, Phase II clinical trial designed to evaluate the efficacy and safety of vibecotamab combined with putelimab in the treatment of locally advanced laryngeal carcinoma.",[318],"Head & Neck Cancer",[320,321,322],"neouAdjuvant","pathological complete response, pCR","vibecotamab combined","2026-04-15",{"date":325,"type":40},"2026-04-20",{"date":327,"type":23},"2026-04-23",{"date":329,"type":23},"2031-04-23",{"name":46,"class":47},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":24,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":102},"100634323","iparomlimab-and-tuvonralimab-plus-chemotherapy-before-surgery-for-stage-iii-lung-cancer-100634323","NCT07538193","Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer","A Study of Iparomlimab and Tuvonralimab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable Stage III-N2b Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Voluntarily join the study and sign the Informed Consent Form (ICF).\n2. ≥18 years old, male or female.\n3. Histologically or cytologically confirmed T\\\u003Csub\\>any\\\u003C\u002Fsub\\>N2b stage NSCLC (American Joint Committee on Cancer \\[AJCC\\] 9th edition). Lymph node status must be confirmed by endobronchial ultrasound (EBUS\u002FEUS) or mediastinoscopy for mediastinal lymph nodes. For left-sided stations 5\u002F6 lymph nodes, parasternal mediastinoscopy is recommended to confirm lymph node status; if mediastinoscopy is not performed, station 5\u002F6 lymph node status is diagnosed based on imaging diagnostic criteria.\n4. Based on MDT assessment (which must include a thoracic surgeon specialized in oncology), the primary NSCLC is deemed to be completely resectable (R0).\n5. At least one measurable lesion as assessed by the investigator per RECIST v1.1.\n6. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n7. Adequate organ function meeting the following requirements (no use of any blood components, cell growth factors, etc., within 14 days before the first dose):\n\n   1. Absolute neutrophil count ≥1.5×10⁹\u002FL;\n   2. Platelet count ≥100×10⁹\u002FL;\n   3. Hemoglobin ≥90 g\u002FL;\n   4. Serum creatinine ≤1.5×upper limit of normal (ULN) or creatinine clearance (CLcr) ≥40 mL\u002Fmin calculated by the Cockcroft-Gault formula;\n   5. Total bilirubin ≤1.5×ULN (patients with Gilbert's syndrome may have ≤3×ULN);\n   6. AST and ALT ≤3×ULN;\n   7. International normalized ratio (INR) or activated partial thromboplastin time (APTT) ≤1.5×ULN, unless the subject is receiving anticoagulant therapy;\n   8. Left ventricular ejection fraction (LVEF) ≥50%.\n8. For female patients of non-surgical sterilized or childbearing potential, must agree to use a medically accepted contraceptive method (e.g., intrauterine device, contraceptive pills, or condoms) during the study treatment period and for 3 months after the study treatment period ends; female patients of childbearing potential who are not surgically sterilized must have a negative serum or urine HCG test within 72 hours before the first dose; and must be non-lactating; for male patients with partners of childbearing potential, must agree to use effective contraception during the trial and for 3 months after the last dose of Iparomlimab\u002FTuvonralimab.\n\nExclusion Criteria:\n\n1. Known presence of EGFR or ALK positive mutations.\n2. History of or concurrent other malignancy within the past 5 years (excluding adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery).\n3. Prior receipt of any anti-tumor therapy for the current lung cancer (e.g., radiotherapy, chemotherapy, targeted therapy, ablation, or other systemic or local anti-tumor therapies).\n4. Current use of immunosuppressants or systemic hormone therapy for immunosuppressive purposes (dose \\>10 mg\u002Fday prednisone or equivalent) and continued use within 2 weeks before enrollment (Note: Inhaled or topical corticosteroids and adrenal replacement steroids are permitted in the absence of active autoimmune disease).\n5. Any active autoimmune disease or history of autoimmune disease, including but not limited to: autoimmune hepatitis, interstitial pneumonia, pulmonary fibrosis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism.\n\n   1. Subjects with hypothyroidism controlled by hormone replacement therapy alone are eligible;\n   2. Subjects with skin diseases not requiring systemic treatment such as vitiligo, psoriasis, alopecia, type 1 diabetes, or childhood asthma that has completely resolved and requires no intervention in adulthood are eligible;\n   3. Patients with asthma requiring medical intervention with steroids are not eligible.\n6. History of allogeneic hematopoietic stem cell transplantation or organ transplantation (except corneal transplantation).\n7. Congenital or acquired immunodeficiency (e.g., HIV-infected individuals).\n8. Uncontrolled active hepatitis B (defined as positive hepatitis B surface antigen \\[HBsAg\\] test at screening with concurrent HBV-DNA test value above the upper limit of normal of the research center's laboratory; subjects with HBV-DNA \\\u003C500 IU\u002FmL measured within 28 days before study drug administration and who have received standard local antiviral therapy for at least 4 weeks and are willing to continue antiviral therapy during the study may be enrolled). Subjects with active hepatitis C (defined as positive hepatitis C virus antibody \\[HCsAb\\] test at screening and positive HCV-RNA).\n9. History of severe allergic reactions to other monoclonal antibodies.\n10. Vaccination with live vaccine within 30 days before the first dose of study treatment (continuing until 90 days after the last dose of study treatment). Note: Live vaccines include but are not limited to measles, mumps, rubella, varicella\u002Fzoster (chickenpox), yellow fever, rabies, BCG, and typhoid vaccines. Inactivated seasonal influenza vaccines, inactivated COVID-19 vaccines, etc., are permitted.\n11. Clinically significant cardiovascular or cerebrovascular diseases, including but not limited to:\n\n    1. Myocardial infarction or unstable angina pectoris within 6 months before the first dose;\n    2. Stroke or transient ischemic attack within 6 months before the first dose;\n    3. Hypertension not controlled with optimal antihypertensive therapy (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg);\n    4. Clinically significant arrhythmia that has been stable for ≥14 days before the first dose may be enrolled;\n    5. Congestive heart failure (New York Heart Association \\[NYHA\\] functional class III-IV);\n    6. Myocarditis.\n12. Systemic infection or other severe infection requiring intravenous antibiotics for \\>7 days within 2 weeks before the first study treatment, or unexplained fever \\>38.5°C during screening or before enrollment (fever due to tumor causes as judged by the investigator is excluded).\n13. Any other condition that, in the investigator's judgment, might affect the study results or lead to premature termination of the study, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring concomitant treatment, severe laboratory abnormalities, or family or social factors, which could affect patient safety.",{"count":339,"type":23},28,[62],"Background: For patients with resectable stage III-N2b non-small cell lung cancer (NSCLC), optimal perioperative treatment strategies remain an area of active investigation. Iparomlimab and tuvonralimab (QL1706) is a novel bifunctional antibody combination targeting PD-1 and CTLA-4, designed to enhance anti-tumor immunity.\n\nObjective: This phase II, single-arm, multicenter study aims to evaluate the efficacy and safety of neoadjuvant iparomlimab and tuvonralimab (QL1706) in combination with platinum-based chemotherapy in patients with resectable stage III-N2b NSCLC.\n\nStudy Design and Methods: A total of 28 patients will be enrolled across approximately 4 centers in China. Eligible patients (aged ≥18 years, ECOG PS 0-1) with histologically or cytologically confirmed, resectable stage III-N2b NSCLC (AJCC 9th edition) will receive three cycles of neoadjuvant therapy every three weeks. Patients with non-squamous carcinoma will receive iparomlimab and tuvonralimab (5 mg\u002Fkg) plus pemetrexed (500 mg\u002Fm²) and carboplatin (AUC 5). Patients with squamous carcinoma will receive iparomlimab and tuvonralimab (5 mg\u002Fkg) plus nab-paclitaxel (260 mg\u002Fm²) and carboplatin (AUC 5). Surgical resection will be performed within 6 weeks following completion of neoadjuvant therapy. Subsequent adjuvant treatment is at the discretion of the investigator.\n\nKey Eligibility Criteria: Key inclusion criteria include pathologically confirmed T\\\u003Csub\\>any\\\u003C\u002Fsub\\>N2b disease with mediastinal nodal status confirmed by EBUS\u002FEUS or mediastinoscopy, and the determination by multidisciplinary team (MDT) assessment that the tumor is completely resectable (R0). Key exclusion criteria include known EGFR or ALK positive mutations, prior anti-cancer therapy for current lung cancer, active autoimmune disease, or uncontrolled hepatitis B or C.\n\nStudy Endpoints: The primary endpoint is the pathological complete response (pCR) rate. Secondary endpoints include major pathological response (MPR) rate, objective response rate (ORR), R0 resection rate, event-free survival (EFS), overall survival (OS), impact on surgical outcomes, and safety. Exploratory endpoints involve biomarker analysis including ctDNA.\n\nSample Size Rationale: Assuming a null hypothesis pCR rate (P0) of 8.8% (based on historical data) and an expected pCR rate (P1) of 28%, with a two-sided α of 5% and 80% power, 24 patients are required. Factoring in a 15% inoperable rate, the total sample size is 28 patients.\n\nStatistical Analysis: The primary endpoint, pCR rate, and other binary endpoints will be summarized with frequencies, percentages, and their 95% confidence intervals calculated using the Clopper-Pearson method. Time-to-event endpoints (EFS, OS) will be analyzed using the Kaplan-Meier method. Safety data will be summarized descriptively.\n\nClinical Trial Information: This study is sponsored by The Second Affiliated Hospital of Air Force Medical University, PLA. The Principal Investigator is Dr. Yan Xiaolong.",[343,344,345],"Carcinoma, Non-Small-Cell Lung (NSCLC)","Neoplasm Staging","Lymphatic Metastasis",{"date":325,"type":40},{"date":348,"type":23},"2026-05",{"date":350,"type":23},"2029-12",{"name":46,"class":47},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":18,"minAge":360,"maxAge":312,"enrollmentInfo":361,"targetDuration":4,"studyType":24,"phases":363,"briefSummary":364,"conditions":365,"keywords":368,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":102},"100633557","phase-1-an-open-label-dose-escalation-study-on-the-safety-tolerability-and-preliminary-efficacy-for-preventing-sap-by-intravenous-pump-delivered-propranolol-in-patients-with-ich-100633557","NCT07528235","An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH","An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing Stroke-Associated Pneumonia of Intravenous Pump-Delivered Propranolol in Patients With Intracerebral Hemorrhage","PROCHASE-DoE","Inclusion Criteria:\n\n* Patients aged \\> 18 and ≤ 80 years of age;\n* Can be treated with the study drug within 24 h of symptom onset;\n* No fever or infection was observed upon admission;\n* NIHSS score ≥10;\n* Supratentorial parenchymal haematoma (≥10 mL);\n* GCS score ≥ 6;\n* Patients or their family members sign informed consent forms.\n\nExclusion Criteria:\n\n* Infections within the last 4 weeks;\n* Use of antibiotics within the last 2 weeks;\n* Known pre-ICH dysphagia;\n* Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes;\n* Previous disability with pre-ICH mRS score ≥ 2;\n* Brainstem hemorrhage;\n* Life expectancy less than 14 days;\n* Death appeared imminent;\n* Pregnancy or within 30 d of delivery;\n* Previous use (within 1 month) of β-blockers or reserpine;\n* Bronchial asthma or COPD;\n* Cardiogenic shock;\n* Degree II-III atrioventricular blocks;\n* Severe or acute heart failure;\n* Heart rate \\\u003C 65 beats\u002Fmin;\n* Known to be allergic to propranolol;\n* Severe liver or renal insufficiency;\n* History of malignant tumors;\n* Currently participating in other interventional clinical trials;\n* Currently, immunosuppressants and immunotherapies are being administered.","10 Years",{"count":362,"type":23},30,[315],"This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.",[366,367],"Intracerebral Hemorrhage","Stroke-Associated Pneumonia (SAP)",[369,366,370,371],"Propranolol","Stroke-Associated Pneumonia","Dose-Escalation Study","2026-04-07",{"date":374,"type":40},"2026-04-14",{"date":376,"type":23},"2026-05-01",{"date":378,"type":23},"2026-11-01",{"name":46,"class":47},{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":312,"enrollmentInfo":387,"targetDuration":4,"studyType":24,"phases":388,"briefSummary":389,"conditions":390,"keywords":391,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":102},"100521088","phase-2-baricitinib-for-moderate-and-severe-traumatic-intracerebral-hemorrhagecontusions-100521088","NCT06065046","Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage\u002FContusions","A Randomized Control Trial of Baricitinib Administration in Patients With Moderate and Severe Traumatic Intracerebral Hemorrhage\u002FContusions","Inclusion Criteria:\n\n1. Age 18 years older and younger than 80 years old.\n2. Definite history of traumatic brain injury.\n3. Admission within≤24 hours after the traumatic brain injury.\n4. CT scans demonstrate intracerebral hemorrhage\u002Fcontusions with and without extracerebral hemorrhage (epi- and sub- dural hemorrhage)\n5. GCS score of 5 or greater and no more than 12 at time of enrollment.\n6. Closed head injury.\n7. Admission without infections\n8. Signed and dated informed consent by the subject, legally authorized representative, or surrogate obtained.\n\nExclusion Criteria:\n\n1. Time of head injury cannot be reliably assessed.\n2. Subjects is considered a candidate for immediate surgical intervention because of severe extracranial injury.\n3. Open head injury.\n4. Pregnancy or parturition within previous 30 days or active lactation.\n5. Use of Janus kinase inhibitors (baricinitib,abroctinib, AG490 and etc.)\n6. Pre-traumatic dementia or disability.\n7. With severe liver, kidney disease, or malignancy, life expectancy is less than 14 days.\n8. Severe pulmonary infection.\n9. Severe or acute heart failure.\n10. Severe infections within previous 30 days.\n11. History of myocardial infarction.\n12. Known sensitivity to baricinitib.\n13. Severe decreases in neutrophil, lymphocyte and platelet counts, severe decrease in hemoglobin.\n14. Severe liver and kidney dysfunction.\n15. Currently participating in other interventional clinical trials.",{"count":286,"type":23},[85],"The purpose of the present study is to study the effect of baricitinib administration on outcome of participants with moderate and severe traumatic intracerebral hemorrhage\u002Fcontusions. A multi-center randomized control trial will be conducted. Participants with a radiological diagnosis of traumatic intracerebral hemorrhage\u002Fcontusions and an initial GCS score of 5-12 will be screened and enrolled in the first 24 hours after traumatic brain injury.",[290],[392,393,394,395,396],"traumatic intracerebral Hemorrhage","traumatic intracerebral Contusions","baricitinib","Janus kinase inhibitor","neuro-inflammatory responses",{"date":398,"type":40},"2026-04-13",{"date":400,"type":40},"2023-11-24",{"date":402,"type":23},"2026-12-31",{"name":46,"class":47},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":312,"enrollmentInfo":412,"targetDuration":4,"studyType":24,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":424,"leadSponsor":425,"locationsCount":102},"100632656","phase-2-intra-arterial-methylprednisolone-after-endovascular-thrombectomy-100632656","NCT07516522","Intra-arterial Methylprednisolone After Endovascular Thrombectomy","Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion","IMPACT-LVO","Inclusion Criteria:\n\n* Age 18-80 years old;\n* The time from onset to randomization was within 24 hours;\n* Large vessel occlusive stroke in the anterior circulation confirmed by CTA\u002FMRA\u002FDSA (Including intracranial segment of internal carotid artery, M1 or M2 segment of middle cerebral artery) and the vessel responsible for the signs and symptoms of acute ischemic stroke;\n* NIHSS score \\>= 6 points\n* Alberta Stroke Program Early Diagnosis (ASPECTS) score of NCCT \\>=3;\n* Successful endovascular thrombectomy (eTICI 2b50-3)\n* Written informed consent signed by patients or their family members\n\nExclusion Criteria:\n\n* Intracranial hemorrhage confirmed by computed tomography (CT) or magnetic resonance imaging (MRI);\n* Prestroke mRS score \\>= 2\n* pregnant or lactating patients\n* Allergy to iodinated contrast media, or methylprednisolone sodium succinate\n* Participating in other clinical research;\n* Inherited\u002Facquired hemorrhagic diathesis (coagulation factor deficiency) or oral anticoagulation with international normalized ratio (INR) \\>1.7\n* History of major bleeding within the past 1 month (gastrointestinal\u002Fgenitourinary hemorrhage)\n* Chronic hemodialysis and severe renal insufficiency (glomerular filtration rate \\\u003C 30ml\u002Fmin\u002F1.73m\\^2 or serum creatinine \\> 220μmol\u002FL (2.5mg\u002Fdl));\n* Terminal illness with life expectancy \\\u003C6 months;\n* Blood glucose \\\u003C 2.8mmol\u002FL (50mg\u002Fdl) or \\> 22.2mmol\u002FL (400mg\u002Fdl);\n* Intracranial aneurysm, arteriovenous malformation, or space-occupying brain tumor with mass effect on imaging\n* Active systemic infectious disease\n* Anticipated inability to complete follow-up\n* Intraoperative DSA showed vascular perforation, dissection, and contrast extravasation;\n* Puncture to recanalization was more than 90 minutes;\n* Total thrombectomy passes \\>3",{"count":413,"type":23},210,[85],"The purpose of IMPACT-LVO trial is to investigate the efficacy and safety of early adjunctive intra-arterial combined with intravenous administration methylprednisolone sodium succinate after successful endovascular thrombectomy in anterior circulation large vessel occlusion patients.\n\nThis is a multicenter, randomized, double-blind, placebo-controlled trial. Acute ischemia stroke patients with anterior circulation large vessel occlusion within 24 hours from last known well will be screened for this trial. Successful recanalization after mechanical thrombectomy (eTICI 2b-3) patients will be randomized 1:1 to either methylprednisolone sodium succinate group or placebo group. The methylprednisolone sodium succinate group patients will receive intra-arterial methylprednisolone sodium succinate 40mg immediately after the recanalization. Then, intravenous administration with methylprednisolone sodium succinate 2mg\u002Fkg in the next 3 days. The placebo group patients will receive intra-arterial and intravenous sterile water for injection.\n\nThe shift on modified Rankin Scale score is designed to detect in the present trial. A sample size of n = 178 patients (n=89 per group) is required. The intention-to-treat principle will be applied to the primary analysis, therefore, to safeguard against dilution of the treatment effect associated with an approximate 15% non-adherence rate (due to loss to follow-up, consent withdrawal and other reasons), we planned to enrol n=210 patients (n=105 per group) for this study. The findings of IMPACT-LVO are likely to have a direct impact on clinical practice.",[417,418,419],"Ischemia Stroke","Thrombectomy","Large Vessel Occlusion","2026-03-31",{"date":422,"type":40},"2026-04-08",{"date":420,"type":40},{"date":44,"type":23},{"name":46,"class":47},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":434,"targetDuration":4,"studyType":24,"phases":435,"briefSummary":436,"conditions":437,"keywords":438,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":102},"100620164","phase-1-neoadjuvant-therapy-with-ensartinib-combined-with-chemotherapy-for-alk-positive-non---small-cell-lung-cancer-nsclc-100620164","NCT07354061","Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)","A Single-arm, Multicenter Clinical Study of Ensartinib Combined With Chemotherapy as Neoadjuvant Therapy for ALK-positive Non-small Cell Lung Cancer (NSCLC) (TD-ENSEMBLE Study)","TD-ENSEMBLE","Inclusion Criteria:\n\n1. Provide informed consent prior to any study-specific procedures.\n2. Aged between 18 and 75 years old (inclusive).\n3. Histologically or cytologically confirmed lung adenocarcinoma via biopsy performed within 60 days prior to study enrollment.\n4. Surgically resectable Stage II-IIIB (N2) lung adenocarcinoma (AJCC 8th Edition TNM Staging).\n5. Confirmed ALK fusion mutation by detection methods recommended by NCCN guidelines.\n6. Presence of at least one accurately measurable lesion, with the longest diameter ≥10 mm on baseline computed tomography (CT) scan (or lymph nodes with a short axis ≥15 mm) and suitable for accurate repeated measurements.\n7. ECOG performance status of 0-1.\n8. Adequate hematological, biochemical, and organ function:\n\n   1. Hemoglobin ≥90 g\u002FL (can be maintained or exceeded via transfusion);\n   2. Absolute neutrophil count ≥1.5×10⁹\u002FL;\n   3. Platelet count ≥90×10⁹\u002FL;\n   4. Total bilirubin ≤2× upper limit of normal (ULN);\n   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN;\n   6. Creatinine ≤1.5× ULN; and creatinine clearance ≥60 mL\u002Fmin.\n9. Adequate cardiopulmonary function suitable for surgical treatment (assessed by ECG, echocardiography, pulmonary function tests, or blood gas analysis).\n10. For female subjects of childbearing potential: Must use highly effective contraception for at least 2 weeks prior to initiation of study drug, have a negative pregnancy test, and not be breastfeeding at the start of dosing. Alternatively, must meet one of the following criteria at screening to demonstrate non-childbearing potential:\n\n    1. Postmenopausal, defined as over 50 years old with amenorrhea for at least 12 months following cessation of all exogenous hormonal therapy.\n    2. Women under 50 years old may be considered postmenopausal if they have amenorrhea for 12 months or more following cessation of exogenous hormone therapy and have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels within the postmenopausal range.\n    3. Documented irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not including tubal ligation.\n11. For male subjects with partners of childbearing potential: Must agree to use effective contraceptive methods during the study period and for 3 months after the last dose of study drug\n\nExclusion Criteria:\n\n1. Presence of squamous cell carcinoma, large cell neuroendocrine carcinoma, or small cell carcinoma components.\n2. Prior exposure to other anti-tumor therapies before enrollment.\n3. Patient is pregnant or breastfeeding.\n4. Current use of (or inability to discontinue use at least 3 weeks prior to receiving the first dose of study treatment) drugs or herbal supplements known to be strong inducers of CYP3A4. All patients must try to avoid concomitant use or ingestion of any drugs, herbal supplements, and\u002For foods known to have CYP3A4 induction effects.\n5. Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, which in the investigator's opinion would compromise the patient's participation in the study or protocol compliance, or active infections including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n6. Prior history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any current evidence of active ILD.\n7. History of hypersensitivity to active or inactive excipients of Ensartinib or drugs with similar chemical structures or classes to Ensartinib, as well as uncontrollable nausea and vomiting, chronic gastrointestinal diseases, inability to swallow formulated medication, or prior extensive bowel resection that would preclude adequate absorption of Ensartinib.\n8. Intolerance to chemotherapy or refusal of chemotherapy.\n9. Any of the following cardiac criteria:\n\n   1. Mean resting corrected QT interval (QTc) \\> 470 msec obtained from three ECGs using the screening ECG machine's QTc value.\n   2. Any clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG, such as left bundle branch block, third-degree heart block, or second-degree heart block.\n   3. Any factors that increase the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death under 40 years of age in first-degree relatives, or any concomitant medication known to prolong the QT interval.\n10. History of definite neurological or psychiatric disorders, including epilepsy or dementia.\n11. Any other conditions deemed by the investigator as unsuitable for enrollment.",{"count":138,"type":23},[315,85],"The goal of this clinical trial is to learn if Ensartinib combined with chemotherapy works as a neoadjuvant treatment for patients with stage II-IIIB (N2) ALK-positive non-small cell lung cancer (NSCLC). It will also learn about the safety of this combination therapy. The main questions it aims to answer are:\n\n* Does Ensartinib combined with chemotherapy lead to a pathological complete response (pCR) in surgically removed tumor tissue after neoadjuvant treatment?\n* What medical problems do participants have when taking Ensartinib combined with chemotherapy? This is a single-arm study, meaning all participants will receive the investigational treatment. There is no placebo or active comparator group. The study will be conducted in two stages; the second stage will proceed only if no special, unexpected, or serious adverse events related to Ensartinib occur during the first stage involving 5 participants.\n\nParticipants will:\n\n* Receive neoadjuvant treatment with Ensartinib (taken orally once daily) plus Pemetrexed and Carboplatin (administered intravenously every 3 weeks) for 9 weeks (3 cycles).\n* Undergo surgical resection within 4 weeks after completing neoadjuvant therapy.\n* Attend regular clinic visits for check-ups, blood tests, and imaging scans (CT, MRI) according to a detailed schedule during the neoadjuvant, surgical, and long-term follow-up periods (up to 10 years).\n* Be monitored for adverse events and survival outcomes.",[264],[439,440,441,442],"Ensartinib","neoadjuvant","ALK - positive","Resectable",{"date":444,"type":40},"2026-04-01",{"date":446,"type":40},"2026-03-25",{"date":448,"type":23},"2030-12-30",{"name":46,"class":47},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":258,"enrollmentInfo":456,"targetDuration":4,"studyType":24,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":102},"100631261","efficacy-and-safety-of-fully-resorbable-sinus-drug-eluting-stents-in-patients-with-eosinophilic-chronic-rhinosinusitis-with-nasal-polyps-after-surgery-a-prospective-randomized-controlled-trial-100631261","NCT07498374","Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial","Part A\n\nInclusion Criteria:\n\n1. Age 18-65 years.\n2. Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP).\n3. Eosinophilic subtype confirmed by pathology (eosinophils \\>27% of total infiltrating inflammatory cells in polyp tissue, OR absolute count \\>55 eosinophils per high-power field (HPF) on H\\&E staining).\n4. Indicated and scheduled for Functional Endoscopic Sinus Surgery (FESS) due to inadequate response to standard medical therapy for \\>3 months, with bilateral endoscopic Nasal Polyp Score (NPS) ≥5 (max 8), each side ≥2, and presenting at least 2 of the following symptoms before screening: nasal blockage\u002Fcongestion, anterior\u002Fposterior nasal discharge, facial pain\u002Fpressure, or reduced\u002Floss of smell.\n5. Voluntarily participates, provides informed consent, and is able to complete questionnaires and follow-up visits.\n\nExclusion Criteria:\n\n1. Previous nasal surgery within 6 months before screening that altered lateral wall structure and precludes polyp assessment.\n2. Allergy to corticosteroids or any component of the fully degradable sinus drug-eluting stent.\n3. Severe systemic disease contraindicating surgery.\n4. Other significant nasal diseases (e.g., sinonasal tumor, fungal sinusitis).\n5. Uncontrolled systemic diseases (e.g., severe cardiac, hepatic, renal dysfunction, diabetes).\n6. Recent use of steroids (30-day washout for parenteral, 14-day for oral, budesonide drops\u002Firrigation, nebulized), immunosuppressants\u002Fbiologics (within 5 terminal half-lives), or leukotriene antagonists\u002Fmodulators prior to baseline.\n7. Recent acute sinusitis episode.\n8. Physical obstruction preventing access to any ethmoid sinus for stent delivery.\n9. Known history or diagnosis of glaucoma, ocular hypertension, or posterior subcapsular cataract.\n10. Pregnant or lactating women.\n11. Participation in another clinical trial within the past 1 month.\n\nPart B\n\nInclusion Criteria:\n\n1. Age 18-65 years.\n2. Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP).\n3. Eosinophilic subtype confirmed by pathology (eosinophils \\>27% of total infiltrating inflammatory cells in polyp tissue, OR absolute count \\>55 eosinophils per high-power field (HPF) on H\\&E staining).\n4. Early recurrence state: \\>3 months post-FESS with standard therapy, no polyps (NPS=0), Lund-Kennedy (LK) edema score ≥2, and LK discharge score ≥2.\n5. Voluntarily participates, provides informed consent, and is able to complete questionnaires and follow-up visits.\n\nExclusion Criteria:\n\n1. Postoperative polyp recurrence in ECRSwNP patients, with any side NPS \\> 0.\n2. Use of oral corticosteroids after the last FESS procedure.\n3. Allergy to corticosteroids or any component of the fully degradable sinus drug-eluting stent.\n4. Other significant nasal diseases (e.g., sinonasal tumor, fungal sinusitis).\n5. Uncontrolled systemic diseases (e.g., severe cardiac, hepatic, renal dysfunction, diabetes).\n6. Recent use of steroids (30-day washout for parenteral, 14-day for oral, budesonide drops\u002Firrigation, nebulized), immunosuppressants\u002Fbiologics (within 5 terminal half-lives), or leukotriene antagonists\u002Fmodulators prior to baseline.\n7. Recent acute sinusitis episode.\n8. Physical obstruction preventing access to any ethmoid sinus for stent delivery.\n9. Known history or diagnosis of glaucoma, ocular hypertension, or posterior subcapsular cataract.\n10. Pregnant or lactating women.",{"count":457,"type":23},192,[62],"This study consists of two parts evaluating the efficacy and safety of a fully degradable sinus drug-eluting stent in patients with eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP).\n\nPart A assesses the efficacy and safety of the stent when used immediately after functional endoscopic sinus surgery (FESS).\n\nPart B evaluates the stent in patients with early postoperative recurrence of ECRSwNP.\n\nThe study aims to answer the following key questions:\n\nDoes the use of the stent reduce the recurrence of nasal polyps?\n\nCan the stent reduce the need for oral corticosteroids?\n\nThe fully degradable sinus drug-eluting stent is compared with intranasal corticosteroids (Part A) and oral corticosteroids (Part B) to determine whether it offers therapeutic benefit in the management of ECRSwNP.\n\nParticipant Procedures:\n\nPart A: Participants will either receive the fully degradable sinus stent or daily intranasal corticosteroids for 6 months. Follow-up visits will occur at Week 2, Week 4, Week 8, Week 12, and Month 6 to record symptoms and adverse events.\n\nPart B: Participants will either receive the fully degradable sinus stent or oral corticosteroids (based on disease progression) for 6 months. Follow-up visits will be conducted at Week 2, Week 4, Week 8, Week 12, and Month 6 for symptom assessment and documentation of adverse events.",[461],"Eosinophilic Chronic Rhinosinusitis With Nasal Polyps",[463,464],"eosinophilic chronic rhinosinusitis with nasal polyps","fully degradable sinus drug-eluting stent",{"date":466,"type":40},"2026-03-27",{"date":468,"type":40},"2026-01-21",{"date":470,"type":23},"2028-12-31",{"name":46,"class":47},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":56,"minAge":57,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":481,"conditions":482,"keywords":483,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":492,"locationsCount":102},"100630992","effect-of-anticoagulant-therapy-on-endometrial-receptivity-and-pregnancy-outcomes-in-infertility-100630992","NCT07494877","Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility","Evaluation of the Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Patients With Infertility Using an Ultrasound Multimodal System","Inclusion Criteria:\n\n* Female patients aged 20 to 45 years.\n\nClinically diagnosed with infertility and planning to undergo embryo transfer or monitored conception cycles.\n\nPatients who have complete baseline clinical data and are willing to undergo multimodal ultrasound evaluation of endometrial receptivity during the window of implantation.\n\nVoluntarily agreed to participate in this observational study and signed the informed consent form for data collection.\n\nExclusion Criteria:\n\n* Presence of congenital uterine malformations (e.g., septate uterus, bicornuate uterus, unicornuate uterus) that significantly alter the endometrial cavity.\n\nPresence of untreated severe intrauterine lesions, such as submucosal fibroids, severe intrauterine adhesions, or endometrial polyps that may mechanically interfere with implantation.\n\nSevere underlying systemic diseases, including but not limited to severe liver or kidney dysfunction, or malignant tumors.\n\nKnown severe bleeding disorders or strict contraindications to anticoagulant medications (for patients in the routine clinical care setting).\n\nPatients who are unable to cooperate with the transvaginal multimodal ultrasound examination or complete the required follow-up for pregnancy outcomes.","45 Years",{"count":189,"type":23},"The purpose of this prospective observational cohort study is to evaluate the effect of routine clinical anticoagulant therapy on endometrial receptivity and subsequent pregnancy outcomes in women with infertility. Researchers will utilize an ultrasound multimodal system to systematically assess endometrial parameters, including thickness, morphology, peristalsis, and blood flow indices. The study aims to enroll approximately 300 infertile women aged 20 to 45 years. Participants will be observed and grouped based on whether they receive anticoagulant medications, such as aspirin or heparin sodium, as part of their standard clinical care. The study will track ultrasound-based receptivity indicators and follow up on pregnancy status and outcomes at 45 and 90 days of gestation. This study is purely observational, and all clinical treatment decisions are made independently of the study protocol.",[192],[484,485,486],"Endometrial Receptivity","Anticoagulant Therapy","Multimodal Ultrasound","2026-03-20",{"date":466,"type":40},{"date":490,"type":40},"2025-09-01",{"date":44,"type":23},{"name":46,"class":47},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":20,"enrollmentInfo":500,"targetDuration":4,"studyType":24,"phases":502,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":4},"100618139","anesthesia-comparison-in-early-stage-small-nsclc-a-multicenter-rct-100618139","NCT07327736","Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT","Comparison Between Spontaneous Breathing-preserving Anesthesia and Double-lumen Endotracheal Intubation Anesthesia in Early-stage Non-small Cell Lung Cancer With a Diameter of ≤ 3 cm: a Prospective, Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n* Age ≤ 75 years;\n* Gender is not limited;\n* Patients with suspected T1 stage non-small cell lung cancer (NSCLC) in preoperative clinical staging, with thin-slice CT showing that the maximum tumor diameter is ≤ 3.0 cm, single or multiple nodules, and the nodules requiring surgical resection are located in the same ipsilateral lung lobe, with the number of nodules resected simultaneously ≤ 3;\n* American Society of Anesthesiologists (ASA) classification ≤ Grade III (preferably Grade I - II is recommended);\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1;\n* Body Mass Index (BMI) \\\u003C 25 kg·m-²;\n* Normal cardiopulmonary function: predicted forced expiratory volume in the first second (FEV1%) \\> 50%, resting blood gas analysis showing arterial oxygen partial pressure (PaO2) ≥ 75 mmHg, arterial carbon dioxide partial pressure (PaCO2) \\\u003C 45 mmHg; ejection fraction (EF) \\> 50%, 6-minute walk distance (6MWD) ≥ 350 m;\n* No severe upper airway lesions, Mallampati classification I - II;\n* No contraindications related to paravertebral nerve block and intercostal nerve block;\n* Estimated surgical time ≤ 150 minutes;\n* Patients have no history of clinically significant cardiac or neurological problems.\n\nExclusion Criteria:\n\n* A history of ipsilateral lung surgery;\n* Interstitial pneumonia, pulmonary fibrosis, severe emphysema, severe chronic obstructive pulmonary disease, acute phase of pulmonary infection, or uncontrolled asthma;\n* Sleep apnea syndrome with anticipated airway difficulty or difficulty in airway management;\n* Preoperative complications including coagulation dysfunction, hypoxemia, hypercapnia, or hepatic\u002Frenal insufficiency;\n* Alteration of anesthesia or surgical plan;\n* Persistent cough or increased risk of high airway secretion reflux;\n* Mental disorders, inability to communicate, or refusal to sign the informed consent form;\n* Participation in other clinical trials within 1 month before this trial;\n* Those who are deemed unfit to participate in this trial by the researchers.",{"count":501,"type":23},410,[62],"This study is a prospective, randomized, controlled study, which intends to enroll patients with suspected early-stage NSCLC (non-small cell lung cancer) with a diameter of ≤ 3 cm as research subjects. The study is conducted in accordance with the Declaration of Helsinki. It has been approved by the Ethics Committee of the Second Affiliated Hospital of Air Force Medical University, and patients or their family members have signed the informed consent form. Patients undergoing VATS (video-assisted thoracic surgery) are enrolled in the Department of Thoracic Surgery of the Second Affiliated Hospital of Air Force Medical University. The patients are randomly divided into two groups: the NIVATS (non-intubated video-assisted thoracic surgery) group and the OLV (one-lung ventilation) group. By observing various perioperative indicators of the patients, the short-term efficacy of the two techniques in patients with early-stage NSCLC is compared, so as to evaluate the safety and effectiveness of the NIVATS surgical treatment method.",[505],"Patients With Suspected Non-small Cell Lung Cancer (NSCLC) at Clinical Stage T1","2026-03-10",{"date":508,"type":40},"2026-03-12",{"date":510,"type":23},"2026-03-15",{"date":512,"type":23},"2032-12-31",{"name":46,"class":47},{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":521,"targetDuration":4,"studyType":24,"phases":523,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":102},"100622544","phase-1-a-prospective-multicenter-phase-ibii-trial-of-ivonescimab-ak112-combined-with-albumin-paclitaxel-and-cisplatin-as-neoadjuvant-therapy-for-escc-100622544","NCT07385001","A Prospective, Multicenter, Phase Ib\u002FII Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC","Phase Ib\u002FII Trial of Atezolizumab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Informed Consent: Written informed consent must be obtained before any study-related procedures are initiated.\n* Age and Gender: Participants must be between 18 and 75 years of age, inclusive of both 18 and 75 years, and may be either male or female.\n* Diagnosis and Stage: Participants must be histologically confirmed to have resectable, locally advanced esophageal squamous cell carcinoma (ESCC) with the following criteria:-T1 N1-N3 M0 or T2-T4a N0-N3 M0 (with T2 ≥ 2 cm or poorly differentiated).\n* Lymph Node Status: No suspicious lymph nodes in the neck region (excluding lymph nodes in the upper thoracic esophageal area) as per neck ultrasound or enhanced CT scan; no evidence of systemic metastasis on imaging.\n* R0 Resectability: The participant is expected to achieve R0 resection.\n* Measurable Lesion: At least one measurable tumor lesion must be present.\n* Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Expected Survival: The participant is expected to have a survival duration of at least 3 months.\n* Thyroid Function: Normal thyroid function is defined as a thyroid-stimulating hormone (TSH) level within the normal range. Participants with baseline TSH levels outside the normal range may still be eligible if total T3 (or free T3) and free T4 levels are within the normal range.\n* Organ Function: Laboratory results must meet the following criteria:\n\nHematology (no blood transfusion or blood component or granulocyte colony-stimulating factor treatment within 14 days): Neutrophil count (NEU) ≥ 1.5 × 10⁹\u002FL (1,500\u002Fmm³); Platelet count (PLT) ≥ 100 × 10⁹\u002FL (100,000\u002Fmm³); Hemoglobin ≥ 90 g\u002FL.\n\nLiver: Total bilirubin (TBil) ≤ 1.5 × upper limit of normal (ULN); or for participants with TBil \\\u003C 1.5 × ULN, direct bilirubin must be within the normal range; Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 × ULN.\n\nRenal: Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance (CrCl) ≥ 60 mL\u002Fmin (using the Cockcroft-Gault formula).\n\nCoagulation: International Normalized Ratio (INR) ≤ 1.5; Prothrombin time (PT) or Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.\n\nCardiac Function: Left ventricular ejection fraction (LVEF) ≥ 50%.\n\n* Pregnancy Testing and Contraception: For screening-period eligible female participants of reproductive age, a serum pregnancy test must be negative. Female or male participants of reproductive capacity must be willing to use a reliable contraceptive method throughout the study period (i.e., from the date of informed consent to 90 days after the last dose of study drug), including but not limited to: abstinence, vasectomy in the male partner, sterilization in the female, effective intrauterine devices, and effective oral contraceptives.\n* Compliance: The participant must be willing and able to comply with the study schedule, including visits, treatment regimen, laboratory tests, and other study requirements.\n\nExclusion Criteria:\n\n* History of Other Malignancies: Participants who have had any other malignancy within 5 years prior to enrollment are excluded, except for those with localized or in situ malignancies such as basal or squamous cell carcinoma, superficial bladder cancer, cervical or breast intraepithelial neoplasia, or other conditions that are considered curable with local therapy.\n* Prior Treatment with PD-1\u002FPD-L1 Inhibitors or Other Immune-Modulating Drugs: Participants who have previously received treatment with PD-1\u002FPD-L1 inhibitors or other drugs targeting T-cell receptors (e.g., CTLA-4, OX-40) or anti-angiogenic agents (e.g., bevacizumab, endostar) are excluded.\n* Systemic Non-Specific Immune Modulation: Participants who have received systemic non-specific immune-modulating therapy (e.g., interleukins, interferons, thymopentin) within 2 weeks prior to the first dose of study drug, or who have used traditional Chinese medicine or herbal preparations with anti-tumor indications within 2 weeks prior to the first dose, are excluded.\n* Active Autoimmune Disease Requiring Systemic Treatment: Participants with active autoimmune diseases requiring systemic treatment (e.g., using disease-modifying antirheumatic drugs, corticosteroids, or immunosuppressants) are excluded. Substitutive treatments (e.g., thyroid hormone, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered as systemic treatment.\n* Brainstem, Meningeal, or Spinal Metastasis or Compression: Participants with brainstem, meningeal, or spinal metastasis, or with evidence of compression, are excluded.\n* Significant Pleural, Pericardial, or Peritoneal Effusion: Participants with clinically significant pleural, pericardial, or peritoneal effusions requiring diuretic therapy and\u002For repeated drainage are excluded.\n* Gastrointestinal Obstruction or Complications Within 6 Months of First Dose: Participants with a history of clinically significant gastrointestinal obstruction, perforation, intra-abdominal abscess, or fistula formation within 6 months prior to the first dose of study drug are excluded.\n* Active Inflammatory Gastrointestinal Diseases: Participants with active inflammatory gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis, radiation enteritis, hemorrhagic enteritis, chronic diarrhea) are excluded.\n* Tumor Encircling Major Vessels or Severe Necrosis\u002FHemorrhage: Participants with imaging findings showing tumor encircling major vessels, significant necrosis, or cavitation, and whose researchers determine that entry into the study would pose a bleeding risk, are excluded.\n* Interstitial Lung Disease ≥ Grade 2: Participants with interstitial lung disease ≥ Grade 2 are excluded.\n* Severe Cardiovascular Disease:\n\nUncontrolled hypertension or pulmonary hypertension; Unstable angina pectoris, myocardial infarction within 6 months prior to the first dose of study drug, coronary artery bypass grafting, or stent implantation; Chronic heart failure with NYHA functional class ≥ 2; Left ventricular ejection fraction (LVEF) \\\u003C 50%;\n\n* Severe arrhythmias requiring drug treatment (excluding atrial fibrillation or paroxysmal supraventricular tachycardia), such as QTcF \\> 450 msec in males or \\> 470 msec in females, complete left bundle branch block, or third-degree heart block; Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 4 weeks prior to the first dose of study drug.\n* Severe Infection Within 4 Weeks Prior to First Dose: Participants with a history of severe infection (e.g., sepsis, bacteremia, or severe pneumonia) within 4 weeks prior to the first dose of study drug, or who have received systemic antimicrobial therapy for an active infection (excluding antiviral treatment for hepatitis B or C) within 2 weeks prior to the first dose, are excluded.\n* Active Tuberculosis or Syphilis: Participants with known active tuberculosis (TB) or syphilis are excluded. Suspected TB cases must be ruled out with clinical evaluation.\n* Positive HIV Antibody or Active Hepatitis B or C:",{"count":522,"type":23},45,[315,85],"A Prospective, Multicenter, Phase Ib\u002FII Trial of Ivonescimab (AK112) Combined with Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced Esophageal Squamous Cell Carcinoma",[90,526,221],"Ivonescimab",[221,90],"2026-01-29",{"date":530,"type":40},"2026-02-03",{"date":532,"type":23},"2026-01-28",{"date":534,"type":23},"2028-01-28",{"name":46,"class":47},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":544,"targetDuration":4,"studyType":24,"phases":546,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":102},"100589300","phase-3-neoadjuvant-treatment-of-toripalimab-combined-with-nab-paclitaxel-and-platinum-versus-neoadjuvant-docetaxel-combined-with-cisplatin-and-5-fluorouracil-dcf-in-esophageal-squamous-cell-carcinoma-100589300","NCT06952621","Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma","A Multicenter, Randomized Controlled Clinical Study Comparing Neoadjuvant Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in the Treatment of Resectable Locally Advanced Esophageal Squamous Cell Carcinoma","TD-NEOE3V3","Inclusion Criteria:\n\n* Patients who meet all of the following criteria are eligible to participate in the study:\n\n  1. Voluntarily sign the written informed consent form;\n  2. Age 18-75 years, inclusive of 18 and 75 years, both male and female;\n  3. Life expectancy of ≥3 months;\n  4. Expected to achieve R0 resection;\n  5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n  6. Patients with resectable locally advanced (T1 N1-3 M0 or T2-4a N0-3 M0 (T2≥3cm or poorly differentiated)) thoracic esophageal squamous cell carcinoma confirmed by histology and who have not previously received treatment;\n  7. No suspicious metastatic lymph nodes in the neck (excluding regional lymph nodes in the upper thoracic esophageal cancer area) as suggested by neck ultrasound or enhanced CT, and no systemic metastasis detected by imaging studies;\n  8. Presence of a definite tumor lesion;\n  9. Good organ function as indicated by screening laboratory test results:\n\n     1. Hematology (no blood transfusions or treatment with blood products or granulocyte colony-stimulating factor within 14 days): Neutrophil count (NEU) ≥1.5×10⁹\u002FL (1,500\u002Fmm³); Platelet (PLT) count ≥100×10⁹\u002FL (100,000\u002Fmm³); Hemoglobin ≥90 g\u002FL.\n     2. Liver: Total bilirubin (TBil) ≤1.5×ULN; or for participants with total bilirubin levels \\\u003C1.5×ULN, direct bilirubin within normal limits; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN;\n     3. Kidney: Serum creatinine ≤1.5×ULN or calculated creatinine clearance (CrCl) ≥60 mL\u002Fmin (using the Cockcroft-Gault formula);\n     4. Coagulation function: International normalized ratio (INR) ≤1.5, and prothrombin time (PT) or activated partial thromboplastin time (APTT) ≤1.5×ULN;\n  10. Fertile males or females of childbearing potential must use effective contraception methods (such as oral contraceptives, intrauterine devices, or barrier methods combined with spermicides) during the trial and continue contraception for 6 months after the end of treatment;\n  11. Good compliance and willingness to cooperate with follow-up visits.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria are ineligible for this study:\n\n  1. Previous treatment with PD-1\u002FPD-L1 agents or drugs targeting another T-cell receptor (e.g., CTLA-4, OX-40, etc.);\n  2. Presence of uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n  3. Active autoimmune disease or suspicion of such, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc., with the exception of type 1 diabetes and hypothyroidism controlled with stable-dose replacement therapy, and skin diseases not requiring systemic treatment (e.g., psoriasis, vitiligo);\n  4. History of interstitial lung disease ≥ Grade 2;\n  5. Received systemic corticosteroids (prednisone \\>10mg\u002Fday or equivalent) or other immunosuppressive drugs within 14 days prior to the first study drug administration;\n  6. History of immunodeficiency, including other acquired or congenital immunodeficiency diseases, history of organ transplantation, or having undergone allogeneic hematopoietic stem cell transplantation or solid organ transplantation;\n  7. Received live vaccine within 4 weeks prior to the first study drug administration;\n  8. Presence of severe cardiovascular and cerebrovascular diseases:\n\n     1. Uncontrolled hypertension or pulmonary arterial hypertension;\n     2. Unstable angina or myocardial infarction, coronary artery bypass grafting, or stent implantation within 6 months prior to study drug administration;\n     3. Chronic heart failure with cardiac function ≥ Grade 2 (New York Heart Association \\[NYHA\\] classification);\n     4. Left ventricular ejection fraction (LVEF) \\\u003C50%;\n     5. Severe arrhythmias requiring drug treatment (excluding atrial fibrillation or paroxysmal supraventricular tachycardia). For example: male QTcF \\>450 msec or female QTcF \\>470 msec, complete left bundle branch block, third-degree atrioventricular block;\n     6. Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months prior to study drug administration;\n  9. Presence of uncontrollable or severe underlying diseases, including but not limited to active infections requiring systemic antibiotic therapy;\n  10. Positive test results for human immunodeficiency virus (HIV) antibodies, active hepatitis B or C. The following cases are allowed to participate in this study:\n\n      1. Positive for hepatitis B core antibody (HBcAb) or hepatitis B surface antigen (HBsAg), but HBV DNA below the detection limit of the study center (negative) or \\\u003C500IU\u002FML, and after clinical treatment and presentation, the investigator determines that there is no active infection;\n      2. Positive for hepatitis C antibody, but HCV RNA below the detection limit of the study center (negative);\n  11. Known active tuberculosis (TB). Patients suspected of having active TB must be excluded by chest X-ray, sputum tests, and clinical symptoms and signs;\n  12. Presence of other active malignancies within the past 2 years, excluding malignancies that are expected to be cured after treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell carcinoma of the skin, or ductal carcinoma in situ of the breast treated with radical surgery);\n  13. History of substance abuse or mental disorders that cannot be controlled;\n  14. Pregnant or breastfeeding women;\n  15. Presence of other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities that, in the investigator's judgment, may increase the risk associated with participation in the study or may interfere with the interpretation of study results.",{"count":545,"type":23},390,[547],"PHASE3","This study is a randomized, controlled, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of neoadjuvant toripalimab in combination with nab-paclitaxel and platinum versus neoadjuvant docetaxel in combination with cisplatin and 5-fluorouracil (DCF) in the treatment of resectable locally advanced esophageal squamous cell carcinoma",[88],[551,552,440],"toripalimab","DCF",{"date":554,"type":40},"2026-01-30",{"date":556,"type":23},"2026-02-01",{"date":558,"type":23},"2028-12-28",{"name":46,"class":47},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":24,"phases":569,"briefSummary":570,"conditions":571,"keywords":573,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":102},"100478032","phase-1-ofatumumab-in-aqp4-igg-seropositive-nmosd-100478032","NCT05504694","Ofatumumab in AQP4-IgG Seropositive NMOSD","Efficacy and Safety of Ofatumumab in AQP4-IgG Seropositive NMOSD: an Open-label, Single-arm, Multicentre Prospective Pilot Study","Inclusion Criteria:\n\n* Diagnosis of NMOSD according to the 2015 International Panel Diagnostic Criteria for NMOSD with AQP4-IgG.\n* Clinical evidence of at least 2 relapses (including first attack) in past 24 months with at least 1 relapse occurring in the preceding 12 months.\n* Adults aged ≥18 years old.\n* Expanded disability status scale (EDSS) score between 0 and 7.5 (inclusive).\n* Provision of written informed consent to participate in this study.\n* Only oral corticosteroids were permitted at screening (≤10mg equivalent per day), which should be terminated within one month.\n* Effective contraception was used for female patients with fertility during the treatment or at least 3 months after stopping medication.\n\nExclusion Criteria:\n\n* Progressive neurological deterioration unrelated to relapses of NMOSD, or presence of neurological findings suspected with PML.\n* Pregnant or breastfeeding patients and those with family planning during the study period.\n* Patients participating in any other clinical therapeutic study at the screening or within 30 days of screening.\n* Patients with splenectomy or history of no spleen, and those with planned surgery (excluding minor surgery) during the study period.\n* Presence of uncontrolled severe concurrent diseases; long-term glucocorticoids or immunosuppressants use due to other autoimmune diseases, or presence of other chronic diseases that cannot receiving immunosuppression.\n* Active infection at within 4 weeks before baseline.\n* Positive for HBV or HCV.\n* Evidence of latent or active tuberculosis (TB).\n* Have received any live or live-attenuated vaccine within 6 weeks before baseline.\n* History of malignancy in past 5 years, including solid tumor, malignant hematopathy and carcinoma in situ.\n* History of severe allergic reactions to biological agents.\n* Inability to provide written informed consent.",{"count":568,"type":23},5,[315,85],"This is an open-label, single-arm, multicentre prospective pilot study to assess the efficacy and safety of ofatumumab in patients with AQP4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) in China.",[572],"Neuromyelitis Optica Spectrum Disorder",[572,574,575],"Aquaporin 4","Ofatumumab",{"date":554,"type":40},{"date":578,"type":40},"2022-06-28",{"date":204,"type":23},{"name":46,"class":47},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":588,"targetDuration":589,"studyType":114,"phases":4,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":102},"100376550","therapeutic-effect-of-different-immunosuppressants-on-non-thymoma-ocular-myasthenia-gravis-a-real-world-study-100376550","NCT04182984","TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study","TREAT-OMG","Inclusion Criteria:\n\n1. Age \\>18 years and\\\u003C75 years;\n2. Clinical Diagnosis of MG with supporting evidence:\n\n   Patients with ocular muscle type MG who have never received treatment meet one of the diagnoses (1) and (2)-(5): (1) The patient's symptoms involve the extraocular muscles, except for drooping eyelids and diplopia, no other clinical symptoms; (2) unequivocal clinical response to pyridostigmine; (3) positive acetylcholine receptor antibody or musk antibody; (4) decrement of more than 10% in repetitive nerve stimulations study (RNS); (5) the \"trembling\" of the single fiber electromyography (SFEMG) is broadened with or without blockade;\n3. Willingness to sample collection, imaging study and other disease-related examinations and assessments;\n4. The results of pregnancy tests for female subjects with fertility during the screening period should be negative and effective contraception was used by the patient and her spouse during the study period;\n5. Patients with informed consent;\n6. Predicted survival time is longer than 3 years.\n\nExclusion Criteria:\n\n1. History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue;\n2. Patients who may have other diseases that may lead to eyelid drooping, peripheral muscle weakness or diplopia;\n3. Age ≤18 years or ≥75 years;\n4. Patients who have been taking glucocorticoids or associated immunosuppressants due to other immune system diseases;\n5. Patients who cannot use immunosuppressants due to other chronic diseases;\n6. Patients who are unable to cooperate with follow-up and self-assessment due to severe mental illness or cognitive impairment;\n7. Pregnant women, lactating women and patients with fertility plans during the trial;\n8. Patients who have suffered from severe infections or malignant tumors in the last 1 month and are unable to receive immunosuppressants treatments;\n9. Patients who are not willing to cooperate with repeated frequency electrical stimulation tests and chest CT examinations;\n10. Patients who are not willing to participate in this study;\n11. Patients who are unable to sign informed consent;\n12. Predicted survival time is shorter than 3 years;\n13. Patients who are not suitable to participated in the trial after researchers' assessment.",{"count":113,"type":23},"3 Years","This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).",[592],"Ocular Myasthenia Gravis",[594],"Ocular myasthenia gravis",{"date":554,"type":40},{"date":597,"type":40},"2019-11-04",{"date":599,"type":23},"2026-06-30",{"name":46,"class":47},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":608,"targetDuration":4,"studyType":24,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":102},"100621952","efficacy-and-safety-of-transcranial-temporal-interference-stimulation-ttis-for-neuropathic-pain-in-neuromyelitis-optica-spectrum-disorder-nmosd-100621952","NCT07377305","Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)","A Single-center, Prospective, Single-arm Clinical Study: Evaluation of the Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)","Inclusion Criteria:\n\n* Patients diagnosed with NMOSD in accordance with the criteria of the International Panel for Neuromyelitis Optica Diagnosis (IPND).\n* Patients were complicated with neuropathic pain, with a DN4 score ≥ 4.\n* NRS score for pain ≥ 4 points, and neuropathic pain has persisted for more than 3 months.\n* Patients receiving biological therapy and\u002For prednisone at a stable dose, with no adjustment of the treatment plan within 30 days before enrollment.\n* Patients who have not adjusted any combination of standard analgesic drugs (including antiepileptic drugs, antidepressants, and opioid drugs) within 30 days before enrollment.\n* Patients or their family members who have signed a written informed consent form.\n\nExclusion Criteria:\n\n* Subjects participating in other clinical studies.\n* Subjects who have used investigational drugs for pain control within 30 days before enrollment.\n* Subjects with a concurrent diagnosis of peripheral neuropathy.\n* Subjects with concurrent active central nervous system diseases.\n* Subjects with cognitive or mental disorders.\n* Subjects who are pregnant, lactating, or planning to become pregnant during the study period.\n* Subjects with severe diseases related to the heart, liver, kidneys, or hematopoietic system.\n* Subjects with implanted devices in the body (such as cardiac pacemakers, nerve stimulators, etc.).\n* Subjects with a history of transcutaneous electrical nerve stimulation (TENS) allergy, latex allergy, or previous intolerance.\n* Subjects with contraindications to MRI examination.\n* Subjects with head skin lesions.\n* Other medical conditions or situations that the researcher deems may affect the achievement of the study objectives.",{"count":609,"type":23},12,[62],"This is an open-label, single-arm, single-center prospective pilot study to assess the efficacy and safety of transcranial temperol interference stimulation in patients with neuromyelitis optica spectrum disorder (NMOSD) complicated by neuropathic pain in China.",[613],"NMO Spectrum Disorder","2026-01-22",{"date":528,"type":40},{"date":617,"type":40},"2025-12-08",{"date":619,"type":23},"2026-09-30",{"name":46,"class":47},""]